Title of Invention	"A SUBSTITUTED STYRYL BENZYLSULFONE COMPOUND"
Abstract	Styryl benzylsulfones of formula (I) are useful as antiproliferative agents, including, for example, anticancer agents. In said formula, (a) (i) at least three of R1, R2, R.3, R4 and R5 are independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro. cyano. carboxyl. hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl, and the balance of said R1, R2, R.3, R4 and R5 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, eyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; and (ii) R6, R7, R.8, R9 and R10 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy. nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; or (b) (i) at least three of R6, R7, R.8, R9 and R10 are independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl, and the balance of said R6, R7, R.8, R9 and R10 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; and (ii) R1, R2, R3, R4 and R5 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 lakoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; or a pharmaceutically acceptable salt thereof.

Title of Invention

"A SUBSTITUTED STYRYL BENZYLSULFONE COMPOUND"

Abstract

Styryl benzylsulfones of formula (I) are useful as antiproliferative agents, including, for example, anticancer agents. In said formula, (a) (i) at least three of R1, R2, R.3, R4 and R5 are independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro. cyano. carboxyl. hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl, and the balance of said R1, R2, R.3, R4 and R5 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, eyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; and (ii) R6, R7, R.8, R9 and R10 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy. nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; or (b) (i) at least three of R6, R7, R.8, R9 and R10 are independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl, and the balance of said R6, R7, R.8, R9 and R10 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; and (ii) R1, R2, R3, R4 and R5 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 lakoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; or a pharmaceutically acceptable salt thereof.

Full Text	Field of the Invention The invention relates to compositions and methods for the treatment of cancer and other proliferate disorders. Background of the Invention Extracellular signals received at transmembrane receptors are relayed into the cells by the signal transduction pathways (Pelech et a/., Science 257:1335 (1992)) which have been implicated in a wide array of physiological processes such as induction of cell proliferation, differentiation or apoptosis (Davis et a/., J. Biol. Chem. 268:14553 (1993)). The Mitogen Activated Protein Kinase (MARK) cascade is a major signaling system by which cells transduce extracellular cues into intracellular responses (Nishida et a/., Trends Biochem. Sci. 18:128 (1993); Blumer et a/., Trends Biochem. Sci. 19:236 (1994)). Many steps of this cascade are conserved, and homologous for MAP kinases have been discovered in different species. In mammalian cells, the Extracellular-Signal-Regulated Kinases (ERKs), ERK-1 and ERK-2 are the archetypal and best-studied members of the MAPK family, which all have the unique feature of being activated by phosphorylation on threonine and tyrosine residues by an upstream dual specificity kinase (Posada et a/., Science 255:212 (1992); Biggs III et a/., Proc. Natl. Acad. Sci. USA 89:6295 (1992); Garner et a/., Genes Dev. 6:1280 (1992)). Recent studies have identified an additional subgroup of MAPKs, known as c-Jun NH2-terminal kinases 1 and 2 (JNK-1 and JNK-2), that have different substrate specificities and are regulated by different stimuli (Hibi et a/., Genes Dev. 7:2135 (1993)). JNKs are members of the class of stress-activated protein kinases (SPKs). JNKs have been shown to be activated by treatment of cells with UV radiation, pro-inflammatory cytokines and environmental stress (Derij'ard et a/., Cell 1025 (1994)). The activated JNK binds to the amino terminus of the c-Jun protein and increases the protein's transcriptional activity by phosphorylating it at ser63 and ser73 (Adler et a/., Proc. Natl. Acad. Sci. USA 89:5341 (1992); Kwokera/., Nature 370:223 (1994)). Analysis of the deduced primary sequence of the JNKs indicates that they are distantly related to ERKs (Davis, Trends Biochem. Sci. 19:470 (1994)). Both ERKs and JNKs are phosphorylated on Tyr and Thr in response to external stimuli resulting in their activation (Davis, Trends Biochem. Sci. 19:470 (1994)). The phosphorylation (Thr and Tyr) sites, which play a critical role in their activation are conserved between ERKs and JNKs (Davis, Trends Biochem. Sci. 19:470 (1994)). However, these sites of phosphorylation are located within distinct dual phosphorylation motifs: Thr-Pro-Tyr (JNK) and Thr-Glu-Tyr (ERK). Phosphorylation of MAPKs and JNKs by an external signal often involves the activation of protein tyrosine kinases (PTKs) (Gille et a/., Nature 358:414 (1992)), which constitute a large family, of proteins encompassing several growth factor receptors and other signal transducing molecules. Protein tyrosine kinases are enzymes which catalyze a well defined chemical reaction: the phosphorylation of a tyrosine residue (Hunter et a/., Annu Rev Biochem 54:897 (1985)). Receptor tyrosine kinases in particular are attractive targets for drug design since blockers for the substrate domain of these kinases is likely to yield an effective and selective antiproliferative agent. The potential use of protein tyrosine kinase blockers as antiproliferative agents was recognized as early as 1981, when quercetin was suggested as a PTK blocker (Graziani et a/., Eur. J. Biochem. 135:583-589 (1983)). The best understood MARK pathway involves extracellular signal-regulated kinases which constitute the Ras/Raf/MEK/ERK kinase cascade (Boudewijn et a/., Trends Biochem. Sci. 20, 18 (1995)). Once this pathway is activated by different stimuli, MARK phosphorylates a variety of proteins including several transcription factors which translocate into the nucleus and activate gene transcription. Negative regulation of this pathway could arrest the cascade of these events. What are needed are new anticancer chemotherapeutic agents which target receptor tyrosine kinases and which arrest the Ras/Raf/MEK/ERK kinase cascade. Oncoproteins in general, and signal transducing proteins in particular, are likely to be more selective targets for chemotherapy because they represent a subclass of proteins whose activities are essential for cell proliferation, and because their activities are greatly amplified in proliferative diseases. What is also needed are new cell antiproliferative agents, and anticancer therapeutics in particular, which are highly selective in the killing of proliferating cells such as tumor cells, but not normal cells. Summary of the Invention It is an object of the invention to provide compounds, compositions and methods for the treatment of cancer and other proliferative diseases. The biologically active compounds are.in the form of styryl benzylsulfones. It is an object of the invention to provide compounds which are selective in killing tumor cells but not normal cells. According to one embodiment of the invention, novel compounds are provided according to formula I (Formula Removed) wherein (a) (i) at least three of R1, R2, R3, R4 and R5 are independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl, and the balance of said R1, R2, R3, R4 and R5 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; and (ii) R6, R7, R8, R9 and R10 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; or (b) (i) at least three of R6, R7, R8, R9 and R10 are independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl, and the balance of said R6, R7, R8, R9 and R10 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; and (ii) R1, R2, R3, R4 and R5 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; or a pharmaceutically acceptable salt thereof. The styryl benzylsulfones are characterized by cis-trans isomerism resulting from the presence of a double bond. The compounds are named according to the Cahn-lngold-Prelog system, the IUPAC 1974 Recommendations, Section E: Stereochemistry, in Nomenclature of Organic Chemistry, John Wiley & Sons, Inc., New York, NY, 4th ed, 1992, p. 127-138. Steric relations around a double bond are designated as "Z" or "E". Both configurations are included in the scope of the present invention. (Formula Removed) According to one embodiment, the benzyl nucleus, that is, the ring system containing R1 through R5 is at least trisubstituted. Thus, in formula I, (i) at least three of R1, R2, R3, R4 and R5 are independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl, and the balance of said R1, R2, R3, R4 and R5 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; and (ii) R6, R7, R8, R9 and R10 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl. According to a preferred sub-embodiment of the aforesaid E-configuration compounds, the benzyl nucleus is penta-substituted with halogen, that is, R1, R2, R3, R4 and R5 are halogen, same or different, and R6, R7, R8, R9 and R10 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl and C1-C6 alkoxy. In some embodiments, R8 is halogen or C1-C6 alkoxy. According to another preferred sub-embodiment of the aforesaid E-configuration compounds, R3 is C1-C6 alkoxy, at least two of R1, R2, R3, R4 and R5 are C1-C6 alkoxy, and the remainder of R1, R2, R3, R4 and R5 are hydrogen. According to another embodiment, the styryl nucleus, that is, the ring system containing R6 through RIO, is at least trisubstituted. Thus, in formula I, (i) at least three of R6, R7, R8, R9 and RIO are independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl, and the balance of said R6, R7, R8, R9 and RIO are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; and (ii) R1, R2, R3, R4 and R5are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy), and trifluoromethyl. According to a preferred sub-embodiment, the compounds have the E-configuration and the styryl nucleus is penta-substituted with halogen, that is, R6, R7, R8, R9 and RIO are halogen, same or different. R1, R2, R3, R4 and R5 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl and C1-C6 alkoxy. In. some such embodiments, R3 is halogen or C1-C6 alkoxy. According to another embodiment, a compound has the E-configuration and is mono-substituted at the 4-position on the benzyl nucleus. R3 is selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; andR1, R2, R3, R4 and R5 are hydrogen. At least three of R6, R7, R8, R9 and RIO are independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl, and the balance of said R6, R7, R8, R9 and RIO are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl. In some embodiments, R3 is halogen and R6, R7, R8, R9 and RIO are preferably selected from hydrogen, halogen and C1-C6 alkoxy, provided that at least three of R6, R7, R8, R9 and RIO .are halogen, C1-C6 alkoxy, or combination thereof. In a preferred sub-embodiment of 4-position substitution on the benzyl nucleus, the compounds have the formula IV: (Formula Removed) wherein R3 and R8 are independently selected from the group consisting of halogen, C1-C6 alkoxy, nitro, cyano, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl. R6 and R1o are independently selected from the group consisting of C1-C6 alkoxy, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy); or a pharmaceutically acceptable salt thereof. In some embodiments, R3 and R8 are independently selected from the group consisting of halogen and C1-C6 alkoxy. R6 and RIO are preferably. C1-C6 alkoxy, more preferably C1-C3 alkoxy. In some embodiments, R3, R6, R8, and RIO are C1-C6 alkoxy, preferably C1-C3 alkoxy. The various alkoxy groups may be the same or different. According to another embodiment, the compound has the Z-configuration, and the benzyl nucleus, that is, the ring system containing Rj through R5, is at least trisubstituted. Thus, in formula I, (i) at least three of RI, R2, R3, R4 and R5 are independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl, and the balance of said RI, R2, R3, R4and R5 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; and (ii) R6, R7, R8, R9 and RIO are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl. In some such embodiments of Z configuration compound, the benzyl nucleus is trisubstituted with C1-C6 alkoxy, that is, two of R1, R2, R3,R4 and R5 are hydrogen and three of R1, R2, R3,R4 and R5 are C1-C6 alkoxy, preferably, methoxy. In such compounds, the styryl nucleus is unsubstituted, or from mono-substituted up to penta-substituted, particularly penta-substitution with halogen. According to another embodiment, the compound has the Z configuration and the styryl nucleus, that is, the ring system containing R6 through RIO, is at least trisubstituted. Thus, in formula I, (i) at least three of R6, R7, R8, R9 and RIO are independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl, and the balance of said R6, R7, R8, R9 and RIO are independently selected from the group consisting of hydrogen, .halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; and (ii) R1, R2, R3,R4 and R5 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy), and trifluoromethyl. According to one such embodiment of Z configuration compound, the styryl nucleus is penta-substituted with halogen. R6, R7, R8, R9 and R10 are halogen, same or different, but preferably fluorine. In some such embodiments where the styryl nucleus is penta-substituted, R1, R2, R3,R4 and R5 are independently selected from the group consisting of hydrogen, halogen C1-C6 alkyl and C1-C6 alkoxy. In some such embodiments, the benzyl nucleus is trisubstituted with C1-C6 alkoxy, that is, two of R1, R2, R3,R4 and R5 are hydrogen and three of R1, R2, R3,R4 and R5 are C1-C6 alkoxy, preferably methoxy. In other such embodiments, the benzyl nucleus is mono-substituted at the 4-position, that is, R1, R2, R3,R4 and R5 are hydrogen, and R3 is other than hydrogen. In some such mono-substitution sub-embodiments, R3 is C1-C6 alkoxy, preferably methoxy, or halogen. According to other embodiments of Z configuration compound, the benzyl nucleus is monosubstituted with halogen, particularly at the 4-position, and the styryl nucleus is at least trisubstituted, preferably with halogen. According to one embodiment of Z configuration compound, R1, R2, R3,R4 and R5 are halogen, same or different, and R6, R7, R8, R9 and R10 are independently selected from the group consisting of hydrogen, halogen, C1-C3 alkyl and C1-C3 alkoxy. According to other embodiments, processes for preparing compounds according to formula I are provided. In one such embodiment, the compound has the E configuration. The compound is prepared by condensing a compound of formula III (Formula Removed) with a compound of formula VI: (Formula Removed) wherein (a) (i) at least three of R1, R2, R3, R4 and R5are independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl, and the balance of said R1, R2, R3, R4 and R5 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; and (ii) R6, R7, R8, R9 and R10 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; or (b) (i) at least three of R6, R7, R8, R9 and R10 are independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl, and the balance of said R6, R7, R8, R9 and RIO are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; and (ii) R1, R2, R3, R4 and R5 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl. The formula III compound may be prepared, for example, by reacting sodium glycollate with a benzyl chloride compound of the formula: (Formula Removed) to form a benzylthioacetic acid compound of the formula: (Formula Removed) which is then oxidized to form a compound of formula III, wherein RI through R5are defined as above. Alternatively, the benzylthioacetic acid intermediate is prepared by reacting a compound of the formula HSCH2COOR where R is C1-C6 alkyl with the aforementioned benzyl chloride compound to form a compound of formula II: (Formula Removed) wherein R1 is C1-C6 alkyl, which is then converted to the corresponding benzylthioacetic acid compound by alkaline or acid hydrolysis. A process for preparing compounds according to formula I having the Z configuration is provided. A sodium benzylthiolate of the formula: (Formula Removed) is reacted with a phenylacetylene of the formula: to form a Z-styryl benzylsulfide of formula la: (Formula Removed) wherein RI through R10 are defined as above. The Z-styryl benzylsulfide is then oxidized to form a compound according to formula I having the Z-configuration The term "alkyl", by itself or as part of another substituent means, unless otherwise stated, a straight or branched chain hydrocarbon radical, including di- and multi-radicals, having the number of carbon atoms designated (i.e. C1-C6 means one to six carbons) and includes straight or branched chain groups. Most preferred is C1-C3 alkyl, particularly ethyl and methyl. The term "alkoxy" employed alone or in combination with other terms means, unless otherwise stated, an alkyl group having the designated number of carbon atoms, as defined above, connected to the rest of the molecule via an oxygen atom, such as, for example, methoxy, ethoxy, 1-propoxy, 2-propoxy and the higher homologs and isomers. Preferred are C1-C3 alkoxy, particularly ethoxy and methoxy. By "dimethylamino (C2-C6 alkoxy)" is meant (CH3)2N(CH2)nO-wherein n is from 2 to 6. Preferably, n is 2 or 3. Most preferably, n is 2, that is, the group is the dimethylaminoethoxy group: (CH3)2NCH2CH2O-. By "halogen" is meant fluorine, chlorine, bromine or iodine. By "phosphonato" is meant the group -PO (OH)2. By "sulfamyl" is meant the group -SO2NH2. Where a substituent on the benzyl or styryl nucleus is an alkyl or alkoxy group, the carbon chain may be branched or straight, with straight being preferred. Preferably, the alkyl and alkoxy groups comprise C1-C3 alkyl and C1-C3 alkoxy, most preferably methyl and methoxy. By "substituted" is meant that an atom or group of atoms has replaced hydrogen as the substituent attached to another group. By "subject" is meant an animal or a human being. A pharmaceutical composition is also provided comprising a pharmaceutically acceptable carrier and one or more compounds of formula I above, or a pharmaceutically acceptable salt of such compound. According to another embodiment of the invention, a method of treating an individual for a proliferative disorder, particularly cancer, is provided, comprising administering to said individual an effective amount of a compound according to formula I, or a pharmaceutically acceptable salt of such compound, alone or in combination with a pharmaceutically acceptable carrier. In another embodiment of the invention, a method of inhibiting growth of tumor cells in an individual afflicted with cancer is provided comprising administering to said individual an effective amount of a compound according to formula I, or a pharmaceutically acceptable salt of such compound, alone or in combination with a pharmaceutically acceptable carrier. In another embodiment, a method of inducing apoptosis of cancer cells, more preferably tumor cells, in an individual afflicted with cancer is provided, comprising administering to said individual an effective amount of a compound according to formula I, or a pharmaceutically acceptable salt of such compound, alone or in combination with a pharmaceutically acceptable carrier. In another embodiment, novel compounds are provided which are useful as intermediates in preparing the compounds of formula I. The intermediates comprise the compounds of formulae II and III: (Formula Removed) wherein R is hydrogen or C1-C6 alkyl; and at least three of R1, R2, R3, R4 and R5 are independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl, and the balance of said R1, R2, R3, R4 and R5 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl. According to another embodiment, novel intermediates useful in preparing the compounds of formula I comprise the compounds of formula V (Formula Removed) wherein: (Formula Removed) R 1is H or C1-C6 .alkyl; and X and are Y independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy), and trifluoromethyl; provided: when Y is hydrogen, X may not be hydrogen, 4-chloro, 4-bromo, 4-fluoro or 4-alkoxy. In one embodiment, X and Y are as defined as above, with the further provision that when Y is hydrogen, X may not be 4-trifluoromethyl, 4-nitro or 4-cyano; and when X is 4-chloro, Y may not be 2-chloro or 3-chloro. According to a preferred embodiment, intermediates are provided according to formula V wherein Y is hydrogen and X is selected from the group consisting of 4-hydroxy, 4-amino and 4-sulfamyl. Detailed Description of the Invention According to the present invention, certain highly substituted styryl benzylsulfone derivatives and pharmaceutically acceptable salts thereof selectively kill various tumor cell types without killing normal cells. At least one of the benzyl or styryl aromatic nuclei is at least tri-substituted. By "substituted" in this context means that an atom or group of atoms has replaced hydrogen as the substituent attached to an aromatic ring carbon atom. According to certain embodiments, the benzyl and/or styryl aromatic nuclei are tri-substituted, that is, only two of RI through R5 are hydrogen, and/or only two of R6 through R1o are hydrogen. Representative combinations of substituents are set forth in Table 1 (Table Removed) Table 1: Tri-Substitution According to certain embodiments, the benzyl and/or styryl aromatic nuclei are tetra-substituted, that is, only one of R1 through R5 is hydrogen, and/or only one of R6 through R10 is hydrogen. Representative combinations of substituents are set forth in Table 2: Table 2: Tetra-Substitution (Table Removed) According to other embodiments, the benzyl and/or styryl aromatic nuclei are penta-substituted, preferably with halogen, most preferably with the same halogen, for example, penta-substitution with fluorine. The pattern of substitution with respect to the position of the substituents on the benzyl or styryl nuclei may comprise any pattern of substitution. For example, tri-substitution may comprise substitution at positions 2, 3 and 4, positions 2, 4 and 5, or positions 2, 4 and 6, for example. Likewise, the pattern of tetra-substitution may comprise, for example, substitution at positions 2, 3, 4 and 5, or positions 2, 3, 5 and 6. According to certain preferred embodiments, the 4-position of the benzyl and/or styryl nuclei is substituted, that is, R3 and/or R8 are other than hydrogen. Preferably, R3 and/or R8are halogen or C1-C6 alkoxy. According to one such embodiment of 4-position substitution, the benzyl nucleus is mono-substituted at its 4 position. R3is selected from the group consisting of halogen, C1-C6 alkoxy, nitro, cyano hydroxyl, phosphonato, amino, sulfamyl, acetoxy, and dimethylamino(C2-C6 alkoxy) and trifluoromethyl; RI, R2, R4 and R5 are hydrogen; and R6, R7, R8, R9 and R1o are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl, wherein at least three of. R6, R7, R8, R9 and R1o are other than hydrogen. Particularly preferred are compounds according to formula IV, and pharmaceutically acceptable salts thereof: (Formula Removed) wherein R3 and R8 are independently selected from the group consisting of halogen, C1-C6 alkoxy, nitro, cyano, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl. R6 and R10 are independently selected from the group consisting of C1-C6 alkoxy, hydroxyl, phosphonato, amino, sulfamyl, acetoxy and dimethylamino(C2-C6 alkoxy). In some embodiments, R3 and R8 are independently selected from the group consisting of halogen and C1-C6 alkoxy. R6 and RIO are preferably C1-C6 alkoxy, more preferably C1-C3 alkoxy. In some embodiments, R3, R6, R8, and R10 are C1-C6 alkoxy, preferably C1-C3 alkoxy. According to another such embodiment of 4-position substitution in formula I, R3 is C1-C6 alkoxy; and two of R1, R2, R4 and R5 are also C1-C6 alkoxy, with the remainder of R1, R2, R4 and R5 being hydrogen, that is, the benzyl nucleus is trisubstituted with C1-C6 alkoxy groups. R6, R7, R8, R9 and R1oare independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl. In each of the above embodiments containing alkoxy substituents on the benzyl and/or styryl nucleus, the alkoxy group is preferably a C1-C3 alkoxy group, must preferably methoxy. Without wishing to be bound by any theory, it is believed that the compounds affect the MARK signal transduction pathway, thereby affecting tumor cell growth and viability. This cell growth inhibition is associated with regulation of the ERK and JNK types of MAPK. Without wishing to be bound by any theory, the styryl sulfones of the present invention may block the phosphorylating capacity of ERK-2. The compounds of the invention have been shown to inhibit the proliferation of tumor cells by inducing cell death. The compounds are believed effective against a broad range of tumor types, including but not limited to the following: breast, prostate, ovarian, lung, colorectal, brain (i.e., glioma) and renal. .The compounds are. also believed effective against leukemic .cells. The compounds do not kill normal cells in concentrations at which tumor cells are killed. The compounds are also believed useful in the treatment of non-cancer proliferative disorders, including but not limited to the following: hemangiomatosis in new born, secondary progressive multiple sclerosis, chronic progressive myelodegenerative disease, neurofibromatosis, ganglioneuromatosis, keloid formation, Paget's disease of the bone, fibrocystic disease of the breast, Peyronie's fibrosis, and Dupuytren's fibrosis, restenosis and cirrhosis. Treatment of this broad range of tumor cells with the styryl benzylsulfone compounds of the invention leads to inhibition of cell proliferation and induction of apoptotic cell death. Tumor cells treated with the compounds of the invention accumulate in the G2/M phase of the cell cycle. As the cells exit the G2/M phase, they appear to undergo apoptosis. Treatment of normal cells with the styryl sulfones does not result in apoptosis. (E)-Styryl benzylsulfones may be prepared by Knoevenagel condensation of aromatic aldehydes with benzylsulfonyl acetic acids. The procedure is described by Reddy et a/., Acta. Chim. Hung. 115:269-71 (1984); Reddy et a/., Sulfur Letters 13:83-90 (1991); Reddy et a/., Synthesis No. 4, 322-323 (1984); and Reddy et a/., Sulfur Letters 7:43-48 (1987), the entire disclosures of which are incorporated herein by reference. According to the Scheme 1 below, Ra and Rb each represent from zero to five substituents on the depicted aromatic nucleus. The benzyl thioacetic acid B is formed by the reaction of sodium thioglycollate and a benzyl chloride A. The benzyl thioacetic acid B is then oxidized with 30% hydrogen peroxide to give a corresponding benzylsulfonyl acetic acid C. Condensation of the benzylsulfonyl acetic acid C with an aromatic aldehyde D via a Knoevenagel reaction in the presence of benzylamine and glacial acetic acid yields the desired (E)-styryl benzylsulfone E. (Formula Removed) The following is a more detailed two-part synthesis procedure for preparing (E)-styryl benzylsulfones according to the above scheme. General Procedure 1: Synthesis (E)-Styryl benzylsulfones Part A. To a solution of (8g, 0.2 mol) sodium hydroxide in methanol (200 ml), thioglycollic acid (0.1 mol) is added slowly and the precipitate formed is dissolved by stirring the contents of the flask. Then an appropriately substituted or unsubstituted benzyl chloride (0.1 mol) is added stepwise and the reaction mixture is refluxed for 2-3 hours. The cooled contents are poured onto crushed ice and neutralized with dilute hydrochloric acid (200 ml). The resulting corresponding benzylthioacetic acid (0.1 mol) is subjected to oxidation with 30% hydrogen peroxide (0.12 mol) in glacial acetic acid (125 ml) by refluxing for 1 hour. The contents are cooled and poured onto crushed ice. The separated solid is recrystalized from hot water to give the corresponding pure benzylsulfonylacetic acid. Part B. A mixture of the benzylsulfonyl acetic acid (10 mmol), an appropriately substituted or unsubstituted aromatic aldehyde (10 mmol), and benzylamine (200 ml) in glacial acetic acid (12 ml) is refluxed for 2-3 hours. The contents are cooled and treated with cold ether (50 ml). Any product precipitated out is separated by filtration. The filtrate is diluted with more ether and washed successively with a saturated solution of sodium bicarbonate (20 ml), sodium bisulfite (20 ml), dilute hydrochloric acid (20 ml) and finally with water (35 ml). Evaporation of the dried ethereal layer yields styryl benzylsulfones as a solid material. According to an alternative to Part A, the appropriate benzylsulfonylacetic acids may be generated by substituting a thioglycollate HSChfeCOOR for thioglycollic acid, where R is an alkyl group, typically C1-C6 alkyl. This leads to the formation of the alkylbenzylthioacetate intermediate (F), (Formula Removed) which is then converted to the corresponding benzyl thioacetic acid B by alkaline or acid hydrolysis. (Z)-Styryl benzylsulfones are prepared by the nucleophilic addition of the appropriate thiol to substituted phenylacetylene with subsequent oxidation of the resulting sulfide by hydrogen peroxide to yield the Z-styryl benzylsulfone. The procedure is generally described by Reddy et a/., Sulfur Letters 13:83-90 (1991), the entire disclosure of which is incorporated herein as a reference. In the first phase of the synthesis, a substituted or unsubstitued sodium benzylthiolate, prepared from an appropriate substituted or unsubstitued sodium benzyl mercaptan, is allowed to react with the appropriate substituted , phenylacetylene forming the pure Z-isomer of the corresponding substituted (Z)-styryl benzylsulfide in good yield. In the second step of the synthesis, the substituted (Z)-styryl benzylsulfide intermediate is oxidized to the corresponding sulfone in the pure Z- isomeric form by treatment with an oxidizing agent, such as hydrogen peroxide. The following is a more detailed two-part synthesis procedure for preparing the substituted (Z)-styryl benzylsulfones. It may be appreciated that at least one of the starting styrene and sodium benzyl mercaptan are at least trisubstituted, in order to form compounds according to formula I. General Procedure 2: Synthesis of substituted (Z)-styryl benzylsulfones. A. To a cooled stirred solution (40°C) of a substituted or unsubstituted styrene (0.5 mol) in chloroform (200 ml) is added dropwise a solution of bromine (0.5 mol) in chloroform (100 ml). After the addition is complete, the contents of the flask are stirred for an additional 30 minutes. Removal of chloroform in rotavapor yields a crystalline solid of a 1,2-dibromoaryl ethane. B. A solution of potassium hydroxide (85 g) in rectified spirit (400 ml) is cooled to room temperature (25°C) and the above 1,2-dibromoaryl ethane (0.33 mol) is added in portions to control the exothermic reaction. After the addition is complete, the reaction mixture is heated to reflux for 6 hours. The contents are then cooled and poured into water (1000 ml). The separated substituted or unsubstituted phenylacetylene is purified either by distillation (in case of liquids) or recrystallization (In case of solids). C. To a refluxing methanolic solution of a substituted or unsubstituted sodium benzylthiolate prepared from 460 mg (0.02g atom) of (i) sodium, (ii) substituted or unsubstituted sodium benzyl mercaptan (0.02 mol) and (iii) 80 ml of absolute methanol, is added a freshly distilled substituted or unsubstituted phenylacetylene. The mixture is refluxed for 20 hours, cooled and then poured on crushed ice. The crude product is filtered, dried and recrystallized from methanol or aqueous methanol to yield pure substituted (Z)-styryl benzylsulfide. D. An ice cold solution of a substituted (Z)-styryl benzylsulfide (3 g) in 30 ml of glacial acetic acid is treated with 7.5 ml of 30% hydrogen peroxide. The reaction mixture is refluxed for 1 hour and poured onto crushed ice. The solid separated is filtered, dried and recrystallized from 2-propanol to yield a pure substituted (Z)-styryl benzylsulfone. The purity of the compound is ascertained by TLC and geometrical configuration is assigned by IR and NMR spectral data. The benzyl thioacetic acid B, benzylsulfonyl acetic acid C, and alkylbenzylthioacetate (F) are novel intermediates which form another aspect of the invention. Accordingly, intermediate compounds useful in the synthesis of the substituted benzylstyryl sulfones comprise the substituted benzylthioacetic acids and esters of formulae II, and the substituted benzylsulfonyl acetic acids of formula III, (Formula Removed) wherein: R1isHorC1-C6alkyl; at least three of R1, R2, R4 and R5 are independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl, and the balance of said R1, R2, R4 and R5 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl. According to preferred embodiments of the intermediates of formulae II and III, at least three of R1, R2, R4 and R5 are independently selected from the group consisting of halogen, C1-C6 alkyl and C1-C6 alkoxy, and the balance of saidR1, R2, R4 and R5 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy. C1-C3 alkyl and C1-C3 alkoxy are the preferred alkyl and alkoxy substituents, with methyl and methoxy being most preferred. According of other preferred embodiments, all of R1, R2, R3, R4 and R5 are halogen, preferably the same halogen, or all are C1-C6 alkoxy, most preferably C1-C3 alkoxy, most preferably methoxy. Other novel intermediates useful in preparing the compounds of formula I comprise the compounds of formulae V (Formula Removed) wherein: (Formula Removed) R1is H orC1-C6alkyl;and X and are Y independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy), and trifluoromethyl; provided: when Y is hydrogen, X may not be hydrogen, 4-chloro, 4- bromo, 4-fluoro or 4-alkoxy. In one embodiment, X and Y are as defined as above, with the further provision that when Y is hydrogen, X may not be 4-trifluoromethyl, 4-nitro or 4-cyano; and when X is 4-chloro, Y may not be 2-chloro or 3-chloro. According to a preferred embodiment, intermediates are provided according to formula V wherein Y is hydrogen and X is selected from the group consisting of 4-hydroxy, 4-amino and 4-sulfamyl. The intermediates may be prepared according to General procedure 1, Part A, above. Representative intermediates prepared according to the present invention, and their respective melting points, include the following (ND = melting point not done): 2,4-dichlorobenzylthioacetic acid, 69-71 °C; 2,4-dichlorobenzylsulfonylacetic acid, 178-180°C; 4-iodobenzylthioacetic acid, 79-81 °C; 4-iodobenzylsulfonylacetic acid 193-196°C; 2-methoxybenzylthioacetic acid, liquid; 2-methoxybenzylsulfonylacetic acid, liquid; 2,4-dimethoxy benzylthioacetic acid, ND; 2,4-dimethoxybenzylsulfonylacetic acid, ND; 4-cyanobenzylthioacetic acid, 80-82°C; 4-cyanobenzylsulfonylacetic acid, 211-213°C; 4-trifluoromethylbenzylthiolacetic acid, ND; 4-trifluoromethylbenzylsulfonylacetic acid, 162-164°C; 2,3,4-trimethoxybenzylthioacetic acid, liquid; 2,3,4-trimethoxybenzylsulfonylacetic acid, 140-144°C; 3,4,5-trimethoxybenzylthioacetic acid, ND; 3,4,5-trimethoxybenzylsulfonylacetic acid, 165-167°C; 2,4,6-trimethoxybenzylthioacetic acid, ND; 2,4,6-trimethoxybenzylsulfonylacetic acid, ND; 2-nitro-4,5-dimethoxybenzylthioacetic acid, ND; 2-nitro-4,5-dimethoxybenzylsulfonylacetic acid, 137-140°C; 3,5-dimethoxybenzylthioacetic acid, liquid; 3,5-dimethoxybenzylsulfonylacetic acid, liquid; 2-methoxy-5-nitrobenzylthioacetic acid, liquid; 2-methoxy-5-nitrobenzylsulfonylacetic acid, 158-160°C; 4-hydroxybenzylthioacetic acid, ND; 4-hydroxybenzylsulfonylacetic acid, ND; 1,2,3,4,5-pentafluorobenzylthioaceticacid, 68-70°C; and 1,2,3,4,5-pentafluorobenzylsulfonylacetic acid, 108-110°C. The present invention is also directed to isolated optical isomers of compounds according to formula I. Certain compounds may have one or more chiral centers. By "isolated" means a compound which has been substantially purified from the corresponding optical isomer(s) of the same formula. Preferably, the isolated isomer is at least about 80%, more preferably at least 90% pure, even more preferably at least 98% pure, most preferably at least about 99% pure, by weight. The present invention is meant to comprehend diastereomers as well as their racemic and resolved, enantiomerically pure forms and pharmaceutically acceptable salts thereof. Isolated optical isomers may be purified from racemic mixtures by well-known chiral separation techniques. According to one such method, a racemic mixture of a compound having the structure of formula I, or chiral intermediate thereof, is separated into 99% wt.% pure optical isomers by HPLC using a suitable chiral column, such as a member of the series of DAICEL CHIRALPAK family of columns (Daicel Chemical Industries, Ltd., Tokyo, Japan). The column is operated according to the manufacturer's instructions. The styryl benzylsulfone compounds of the present invention may be derivatized with a chemical group to permit conjugation to a carrier molecule, for the purpose of raising antibodies to the styryl sulfones. Suitable derivatizing chemistries are well-known to those skilled in the art. Preferably, the derivative comprises a carboxylic acid derivative. The carrier may comprise any molecule sufficiently large to be capable of generating an immune response in an appropriate host animal. One such preferred carrier is keyhole limpet haemocyanin (KLH). The compounds of the present invention may take the form or pharmaceutically acceptable salts. The term "pharmaceutically acceptable salts", embraces salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. The nature of the salt is not critical, provided that it is pharmaceutically-acceptable. Suitable pharmaceutically acceptable acid addition salts may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, example of which are formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzole, anthranilic, mesylic, 4-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, 2-hydroxyethanesulfonic, toluenesulfonic, sulfanilic, cyclohexylaminosulfonic, stearic, alginic, beta-hydroxybutyric, salicylic, galactaric and galacturonic acid. Suitable pharmaceutically acceptable base addition salts of compounds of formula I include metallic salts made from calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine. All of these salts may be prepared by conventional means from the corresponding compound of formula I by reacting, for example, the appropriate acid or base with the compound of formula I. The compounds of the invention may be administered in the form of a pharmaceutical composition, in combination with a pharmaceutically acceptable carrier. The active ingredient in such formulations may comprise from 0.1 to 99.99 weight percent. By "pharmaceutically acceptable carrier" is meant any carrier, diluent or excipient which is compatible with the other ingredients of the formulation and not deleterious to the recipient. The compounds of the invention may be administered to individuals (mammals, including animals and humans) afflicted with cancer. The compounds are also useful in the treatment of non-cancer proliferative disorders, that is, proliferative disorders which are characterized by benign indications. Such disorders may also be known as "cytoproliferative" or "hyperproliferative" in that cells are made by the body at an atypically elevated rate. Such disorders include, but are not limited to, the following: hemangiomatosis in new born, secondary progressive multiple sclerosis, chronic progressive myelodegenerative disease, neurofibromatosis, ganglioneuromatosis, keloid formation, Paget's disease of the bone, fibrocystic disease of the breast, Peyronie's fibrosis and Dupuytren's fibrosis, restenosis and cirrhosis. The compounds may be administered by any route, including oral and parenteral administration. Parenteral administration includes, for example, intravenous, intramuscular, intraarterial, intraperitoneal, intranasal, rectal, intravaginal, intravesical (e.g., to the bladder), intradermal, topical or subcutaneous administration. Also contemplated within the scope of the invention is the instillation of drug in the body of the patient in a controlled formulation, with systemic or local release of the drug to occur at a later time. For example, the drug may localized in a depot for controlled release to the circulation, or for release to a local site of tumor growth. The compounds of the invention may be administered in the form of a pharmaceutical composition, in combination with a pharmaceutically acceptable carrier. The active ingredient in such formulations may comprise from 0.1 to 99.99 weight percent. By "pharmaceutically acceptable carrier" is meant any carrier, diluent or excipient which is compatible with the other ingredients of the formulation and not deleterious to the recipient. The active agent is preferably administered with a pharmaceutically acceptable carrier selected on the basis of the selected route of administration and standard pharmaceutical practice. The active agent may be formulated into dosage forms according to standard practices in the field of pharmaceutical preparations. See Alphonso Gennaro, ed., Remington's Pharmaceutical Sciences, 18th Ed., (1990) Mack Publishing Co., Easton, PA. Suitable dosage forms may comprise, for example, tablets, capsules, solutions, parenteral solutions, troches, suppositories, or suspensions. For parenteral administration, the active agent may be mixed with a suitable carrier or diluent such as water, an oil (particularly a vegetable oil), ethanol, saline solution, aqueous dextrose (glucose) and related sugar solutions, glycerol, or a glycol such as propylene glycol or polyethylene glycol. Solutions for parenteral administration preferably contain a water soluble salt of the active agent. Stabilizing agents, antioxidizing agents and preservatives may also be added. Suitable antioxidizing agents include sulfite, ascorbic acid, citric acid and its salts, and sodium EDTA. Suitable preservatives include benzalkonium chloride, methyl- or propyl-paraben, and chlorbutanol. The composition for parenteral administration may take the form of an aqueous or nonaqueous solution, dispersion, suspension or emulsion. For oral administration, the active agent may be combined with one or more solid inactive ingredients for the preparation of tablets, capsules, pills, powders, granules or other suitable oral dosage forms. For example, the active agent may be combined with at least one excipient such as fillers, binders, humectants, disintegrating agents, solution retarders, absorption accelerators, wetting agents absorbents or lubricating agents. According to one tablet embodiment, the active agent may be combined with carboxymethylcellulose calcium, magnesium stearate, mannitol and starch, and then formed into tablets by conventional tableting methods. The specific dose of compound according to the invention to obtain therapeutic benefit will, of course, be determined by the particular circumstances of the individual patient including, the size, weight, age and sex of the patient, the nature and stage of the disease, the aggressiveness of the disease, and the route of administration. For example, a daily dosage of from about 0.05 to about 50 mg/kg/day may be utilized. Higher or lower doses are also contemplated. The practice of the invention is illustrated by the following non-limiting examples. . For each (E) configuration compound, the substituted benzylsulfonyl acetic acid was made according to Part A of General Procedure 1: Synthesis (E)-Styryl Benzylsulfones, above. Some of the styryl benzylsulfone compounds were recrystalized from 2-propanol and the purity was checked by thin layer chromatography. Each (Z) configuration compound is prepared by following General Procedure 2: Synthesis (Z)-Styryl Benzylsulfones, above. For brevity, only the principal reactants are listed in each example, it being understood that the principal reactants are made from precursors as set forth in the General Procedure, and then combined under the conditions set forth in the General Procedure. Example 1 (E)-2,3,4,5,6-Pentafluorostyryl-4-fluorobenzylsulfone A solution of 4-fluorobenzylsulfonylacetic acid (10 mmol) and pentafluorobenzaldehyde (10mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 133-136°C, was obtained in 80% yield. Example 2 (E)-2,3,4,5,6-Pentafluorostyryl-4-chlorobenzylsulfone A solution of 4-chlorobenzylsulfonylacetic acid (10 mmol) and pentafluorobenzaldehyde (10mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 147-148°C, was obtained in 82% yield. Example 3 (E)-2,3,4,5,6-Pentafluorostyryl-4-bromobenzylsulfone A solution of 4-bromobenzylsulfonylacetic acid (10 mmol) and pentafluorobenzaldehyde (10mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 163-164°C, was obtained in 85% yield. Example 4 (E)-4-Fluorostyryl-2,3,4,5,6-pentafluorobenzylsulfone A solution of pentafluorobenzylsulfonylacetic acid (10 mmol) and 4-fluorobenzaldehyde (10mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 133-136°C, was obtained in 78% yield. Example 5 (E)-4-Chlorostyryl-2,3,4,5,6-pentafluorobenzylsulfone A solution of pentafluorobenzylsulfonylacetic acid (10 mmol) and 4-chlorobenzaldehyde (10mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 154-155°C, was obtained in 80% yield. Example 6 (E)-4-Bromostyryl-2,3,4,5,6-pentafluorobenzylsulfone A solution of pentafluorobenzylsulfonylacetic acid (10 mmol) and 4-bromobenzaldehyde (10mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 176-177°C, was obtained in 92% yield. Example 7 (E)-2,3,4,5,6-Pentafluorostyryl-3,4-dichlorobenzylsulfone A solution of 3,4-dichlorobenzylsulfonylacetic acid (10 mmol) and pentafluorobenzaldehyde (10mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 171-173°C, was obtained in 84% yield. Example 8 (E)-2,3,4,5,6-Pentafluorostyryl-2,3,4,5,6-pentafluorobenzylsulfone A solution of pentafluorobenzylsulfonylacetic acid (10 mmol) and pentafluorobenzaldehyde (10mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 137-139°C, was obtained in 84% yield. Example 9 (E)-2,3,4,5,6-Pentafluorostyryl-4-iodobenzylsulfone A solution of 4-iodobenzylsulfonylacetic acid (10 mmol) and pentafluorobenzaldehyde (10mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 178-181°C, was obtained in 51% yield. Example 10 (E)-2-Hydroxy-3,5-dinitrostyryl-4-fluorobenzylsufone A solution of 4-fluorobenzylsulfonylacetic acid (10mmol) and 2-hydroxy-3,5-dinitrobenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 211-212°C, was obtained in 54% yield. Example 11 (E)-2-Hydroxy-3,5-dinitrostyryl-4-bromobenzylsufone A solution of 4-bromobenzylsulfonylacetic acid (10 mmol) and 2-hydroxy-3,5-dinitrobenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 207-209°C, was obtained in 52% yield. Example 12 (E)-2-Hydroxy-3,5-dinitrostyryl-4-chlorobenzylsufone A solution of 4-chlorobenzylsulfonylacetic acid (10 mmol) and 2-hydroxy-3,5-dinitrobenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 204-205°C, was obtained in 51% yield. Example 13 (E)-2-Hydroxy-3,5-dinitrostyryl-2,4-dichlorobenzyIsufone A solution of 2,4-chlorobenzylsulfonylacetic acid (10 mmol) and 2-hydroxy-3,5-dinitrobenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 212-213°C, was obtained in 56% yield. Example 14 (E)-2,4,6-Trimethoxystyryl-4-methoxybenzylsulfone A solution of 4-methoxybenzylsulfonylacetic acid (10 mmol) and 2,4,6-trimethoxybenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 142-144°C, was obtained in 52% yield. Example 15 (E)-3-Methyl-2,4-dimethoxystyryl-4-methoxybenzylsulfone A solution of 4-methoxybenzylsulfonylacetic acid (10 mmol) and 3-methyl-2,4-dimethoxybenzaldehye (10mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 160-161 °C, was obtained in 52% yield. Example 16 (E)-3,4,5-Trimethoxystyryl-4-methoxybenzylsulfone A solution of 4-methoxybenzylsulfonylacetic acid (10mmol) and 3,4,5-trimethoxybenzaldehyde (10mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 138-140°C, was obtained in 54% yield. Example 17 (E)-3,4,5-Trimethoxystyryl-2-nitro-4,5-dimethoxybenzylsulfone A solution of 2-nitro-4,5-dimethoxybenzylsulfonylacetic acid (10mmol) and 3,4,5-trimethoxybenzaldehyde (10mmol) was subjected to the General Procedure 1, Part B. The title compound was obtained. Example 18 (E)-2,4,6-Trimethoxystyryl-2-nitro-4,5-dimethoxybenzylsulfone A solution of 2-nitro-4,5-dimethoxybenzylsulfonylacetic acid (10mmol) and 2,4,6-trimethoxybenzaldehyde (10mmol) was subjected to the General Procedure 1, Part B. The title compound was obtained. Example 19 (E)-3-Methyl-2,4-dimethoxystyryl-2-nitro-4,5-dimethoxybezylsulfone A solution of 2-nitro-4,5-dimethoxybenzylsulfonylacetic acid (10mmol) and 3-methyl-2,4-dimethoxybenzaldehyde (10mmol) was subjected to the General Procedure 1, Part B. The title compound was obtained. Example 20 (E)-2,3,4-Trifluorostyryl-4-fluorobenzylsulfone A solution of 4-fluorobenzylsulfonylacetic acid (10 mmol) and 2,3,4-trifluorobenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 128-129°C, was obtained in 72% yield. Example 21 (E)-2,3,4-Trifluorostyryl-4-chlorobenzylsulfone A solution of 4-chlorobenzylsulfonylacetic acid (10 mmol) and 2,3,4-trifluorobenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 141-142°C, was obtained in 78% yield. Example 22 (E)-2,6-Dimethoxy-4-hydroxystyryl-4-methoxybenzylsulfone A solution of 4-methoxybenzylsulfonylacetic acid (10 mmol) and 2,6-dimethoxy-4-hydroxybenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 134-136°C, was obtained in 58% yield. Example 23 (E)-2,3,5,6-Tetrafluorostyryl-4-methoxybenzylsulfone A solution of 4-methoxybenzylsulfonylacetic acid (10 mmol) and 2,3,5,6-tetrafluorobenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 154-156°C, was obtained in 56% yield. Example 24 (E)-2,4,5-Trimethoxystyryl-4-methoxybenzylsulfone A solution of 4-methoxybenzylsulfonylacetic acid (10 mmol) and 2,4,5-trimethoxybenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 146-148°C, was obtained in 66% yield. Example 25 (E)-2,3,4-Trimethoxystyryl-4-methoxybenzylsulfone A solution of 4-methoxybenzylsulfonylacetic acid (10 mmol) and 2,3,4-trimethoxybenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 154-156°C, was obtained in 52% yield. Example 26 (E)-3-Nitro-4-hydroxy-5-methoxystyryl-4-methoxybenzylsulfone A solution of 4-methoxybenzylsulfonylacetic acid (10 mmol) and 3-nitro-4-hydroxy-5-methoxybenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 203-205°C, was obtained in 56% yield. Example 27 (E)-3,4-Dimethoxy-6-nitrostyryl-4-methoxybenzylsulfone A solution of 4-methoxybenzylsulfonylacetic acid (10 mmol) and 3,4-dimethoxy-6-nitrobenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 139-141°C, was obtained in 54% yield. Example 28 (E)-3,4-Dimethoxy-5-iodostyryl-4-methoxybenzylsulfone A solution of 4-methoxybenzylsulfonylacetic acid (10 mmol) and 3,4-dimethoxy-5-iodobenzaldehyde -(10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 160-161°C, was obtained in 58% yield. Example 29 (E)-2,6-Dimethoxy-4-fluorostyryl-4-methoxybenzylsulfone A solution of 4-methoxybenzylsulfonylacetic acid (10 mmol) and 2,6-dimethoxy-4-fluorobenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 146-148°C, was obtained in 55% yield. Example 30 (E)-2-Hydroxy-4,6-dimethoxystyryI-4-methoxybenzylsulfone A solution of 4-methoxybenzylsulfonylacetic acid (10 mmol) and 2-hydroxy-4,6-dimethoxybenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound was obtained. Example 31 (E)-2,4,6-Trimethylstyryl-4-methoxybenzylsulfone A solution of 4-methoxybenzylsulfonylacetic acid (10 mmol) and 2,4,6-trimethylbenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 97-99°C, was obtained in 51% yield. Example 32 (E)-2,4,6-Trimethoxystyryl-4-chlorobenzylsulfone A solution of 4-chlorobenzylsulfonylacetic acid (10 mmol) and 2,4,6-trimethoxybenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 181-183°C, was obtained in 54% yield. Example 33 (E)-2,6-Dimethoxy-4-fluorostyryl-4-chlorobenzylsulfone A solution of 4-chlorobenzylsulfonylacetic acid (10 mmol) and 2,6-dimethoxy-4-fluorobenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 119-121°C, was obtained in 55% yield. Example 34 (E)-2-Hydroxy-4,6-dimethoxystyryl-4-chlorobenzylsulfone A solution of 4-chlorobenzylsulfonylacetic acid (10 mmol) and 2-hydroxy-4,6-dimethoxybenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound was obtained. Example 35 (E)-2,4,6-Trimethoxystyryl-4-bromobenzylsulfone A solution of 4-bromobenzylsulfonylacetic acid (10 mmol) and 2,4,6-trimethoxybenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 178-181°C, was obtained in 54% yield. Example 36 (E)-2,6-Dimethoxy-4-fluorostyryl-4-bromobenzylsulfone A solution of 4-bromobenzylsulfonylacetic acid (10 mmol) and 2,6-dimethoxy-4-fluorobenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 116-118°C, was obtained in 58% yield. Example 37 (E)-2,4,6-Trimethoxystyryl-2,3,4-trimethoxybenzylsulfone A solution of 2,3,4-trimethoxybenzylsulfonylacetic acid (10 mmol) and 2,4,6-trimethoxybenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 94-96°C, was obtained in 52% yield. Example 38 (E)-2,6-Dimethoxystyryl-2,3,4-trimethoxybenzylsulfone A solution of 2,3,4-trimethoxybenzylsulfonylacetic acid (10 mmol) and 2,6-dimethoxybenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 110-112°C, was obtained in 54% yield. Example 39 (E)-2,4,6-Trimethoxystyryl-,3,4,5-trimethoxybenzylsulfone A solution of 3,4,5-trimethoxybenzylsulfonylacetic acid (10 mmol) and 2,4,6-trimethoxybenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 151-153°C, was obtained in 54% yield. Example 40 (E)-2,6-Dimethoxystyryl-3,4,5-trimethoxybenzylsulfone A solution of 3,4,5-trimethoxybenzylsulfonylacetic acid (10 mmol) and 2,6-dimethoxybenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 146-149°C, was obtained in 53% yield. Example 41 (E)-4-Fluorostyryl-2,3,4-trimethoxybenzylsulfone A solution of 2,3,4-trimethoxybenzylsulfonylacetic acid (10 mmol) and 4-fluorobenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 96-99°C, was obtained in 68% yield. Example 42 (Z)-2,4,6-trifluorostyryl-4-methylbenzylsulfone A solution of 2,4,6-trifluorophenylacetylene (0.02 mol), 4-methylbenzyl mercaptan (0.02 mol) and metallic sodium (0.02g atom) is subjected to General Procedure 2 to form (Z)-2,4,6-trifluorostyryl-4-methylbenzylsulfide. The title compound is obtained following oxidation of the sulfide, according to General Procedure 2. Example 43 (Z)-pentafiuorostyryl-4-chlorobenzylsulfone A solution of pentafluorophenylacetylene (0.02 mol), 4-chlorobenzyl mercaptan (0.02 mol) and metallic sodium (0.02g atom) is subjected to General Procedure 2 to form (Z)-pentafluorostyryl-4-chlorobenzylsulfide. The title compound is obtained following oxidation of the sulfide, according to General Procedure 2. Example 44 (Z)-pentafluorostyryl-4-methoxybenzylsulfone A solution of pentafluorophenylacetylene (0.02 mol), 4-methoxybenzyl mercaptan (0.02 mol) and metallic sodium (0.02g atom) is subjected to General Procedure 2 to form (Z)-pentafluorostyryl-4-methoxybenzylsulfide. The title compound is obtained following oxidation of the sulfide, according to General Procedure 2. Example 45 (Z)-pentafluorostyryl-2,3,4-trimethoxybenzylsulfone A solution of pentafluorophenylacetylene (0.02 mol), 2,3,4-trimethoxybenzyl mercaptan (0,02 mol) and metallic sodium (0.02g atom) is subjected to General Procedure 2 to form (Z)-pentafluorostyryl-2,3,4-trimethoxybenzylsulfide. The title compound is obtained following oxidation of the sulfide, according to General Procedure 2. Example 46 (Z)-pentafluorostyryl-3,4,5-trimethoxybenzylsulfone A solution of pentafluorophenylacetylene (0.02 mol), 3,4,5-trimethoxybenzyl mercaptan (0.02 mol). and metallic sodium .(0.02g atom) is subjected to General Procedure 2 to form (Z)-pentafluorostyryl-3,4,5-trimethoxybenzylsulfide. The title compound is obtained following oxidation of the sulfide, according to General Procedure 2. Example 47 (Z)-pentafluorostyryl-2,4,6-trimethoxybenzylsulfone A solution of pentafluorophenylacetylene (0.02 mol), 2,4,6-trimethoxybenzyl mercaptan (0.02 mol) and metallic sodium (0.02g atom) is subjected to General Procedure 2 to form (Z)-pentafluorostyryl-2,4,6-trimethoxybenzylsulfide. The title compound is obtained following oxidation of the sulfide, according to General Procedure 2. Example 48 (Z)-3-methoxy-4-acetoxystyryl-2,4,5-trimethoxybenzylsulfone A solution of 3-methoxy-4-acetoxyphenylacetylene (0.02 mol), 2,4,5-trimethoxybenzyl mercaptan (0.02 mol) and metallic sodium (0.02g atom) is subjected to General Procedure 2 to form (Z)-3-methoxy-4-acetoxystyryl-2,4,5-trimethoxybenzylsulfide. The title compound is obtained following oxidation of the sulfide, according to General Procedure 2. Example 49 (Z)-3,4-dihydroxystyryl-2,4,6-trimethoxybenzylsulfone A solution of 3,4-dihydroxyphenylacetylene (0.02 mol), 2,4,6-trimethoxybenzyl mercaptan (0.02 mol) and metallic sodium (0.02g atom) is subjected to General Procedure 2 to form (Z)-3,4-dihydroxystyryl-2,4,6,-trimethoxybenzylsulfide. The title compound is obtained following oxidation of the sulfide, according to General Procedure 2. Example 50 (Z)-2,4,6-trifluorostyryl-4-nitrobenzylsulfone A solution of 2,4,6-trifluorophenylacetylene (0.02 mol), 4-nitrobenzyl mercaptan (0.02 mol) and metallic sodium (0.02g atom) is subjected to General Procedure 2 to form (Z)-2,4,6-trifluorostyryl-4-nitrobenzylsulfide. The title compound is obtained following oxidation of the sulfide, according to General Procedure 2. Example 51 (Z)-2-hydroxystyryl-2,4,6-trimethoxybenzylsulfone A solution of 2-hydroxyphenylacetylene (0.02 mol), 2,4,6-trimethoxybenzyl mercaptan (0.02 mol) and metallic sodium (0.02g atom) is subjected to General Procedure 2 to form (Z)-2-hydroxystyryl-2,4,6-trimethoxybenzylsulfide. The title compound is obtained following oxidation of the sulfide, according to General Procedure 2. Example 52 (Z)-2-phosponatostyryl-2,3,4-trimethoxybenzylsulfone A solution of 2-phosphonatophenylacetylene (0.02 mol), 2,3,4-trimethoxybenzyl mercaptan (0.02 mol) and metallic sodium (0.02g atom) is subjected to General Procedure 2 to form (Z)-2-phosponatostyryl-2,3,4-trimethoxybenzylsulfide. The title compound is obtained following oxidation of the sulfide, according to General Procedure 2. Example 53 (Z)-4-phosponatostyryl-2,4,6-trimethoxybenzylsulfone A solution of 4-phosphonatophenylacetylene (0.02 mol), 2,3,4-trimethoxybenzyl mercaptan (0.02 mol) and metallic sodium (0.02g atom) is subjected to the General Procedure to form (Z)-4-phosponatostyryi-2,4,6-trimethoxybenzylsulfide. The title compound is obtained following oxidation of the sulfide, according to the General Procedure. Effect of (E)-Styryl Benzylsulfones on Tumor Cell Lines - Protocol 1 A. Cells. The effect of the (E)-styryl benzylsulfones on normal fibroblasts and on tumor cells of prostate, colon, lung and breast origin was examined utilizing the following cell lines: prostate tumor cell line DU-145; colorectal carcinoma cell line DLD-1; non-small cell lung carcinoma cell line H157; and breast tumor cell line BT-20. BT-20 is an estrogen-unresponsive cell line. NIH/3T3 and HFL are normal murine and human fibroblasts, respectively. BT-20, DLD-1 and H157 were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum supplemented with penicillin and streptomycin. DU145 was cultured in RPMI with 10% fetal bovine serum containing penicillin and streptomycin. NIH3T3 and HFL cells were grown in DMEM containing 10% calf serum supplemented with penicillin and streptomycin. All cell cultures were maintained at 37°C in a humidified atmosphere of 5% CO2. B. Treatment with Styryl Benzylsulfones and Viability Assay Cells were treated with test compound at 2.5 µM concentration and cell viability was determined after 96 hours by the Trypan blue exclusion method. Each compound tested (Exs. 1-16, 20, 21, 23-29, 31-33 and 35-40) showed activity, inducing cell death against all tumor cell lines, in at least 5-10% of the treated cells. Normal cells HFL and NIH 3T3 were treated with the same compounds under the same conditions of concentration and time. The normal cells displayed 5% growth inhibition but no appreciable cell death. Effect of (Z)-Styryl Benzylsulfones on Tumor Cell Lines - Protocol 2 In a variation of the above assay, the effect of the (Z)-styryl benzylsulfones on normal fibroblasts and on tumor cells may be demonstrated by the assay described by Latham ef. a/., Oncogens 12:827-837 (1996). Normal diploid lung human fibroblasts (HFL-1) or tumor cells (e.g., prostate, colo-rectal, breast, glial, pancreatic ovarian or leukemic) are plated in 6-well dishes at a cell density of 1.0 x 10s cells per 35-mm2 well. The plated cells are treated 24 hours later with various concentrations of styrylbenzylsulfone dissolved in dimethyl sulfoxide (DMSO). The total number of viable cells is determined 96 hours later by trypsinizing the wells and counting the number of viable cells, as determined by trypan blue exclusion, using a hemacytometer. Normal HFL are treated with the same compounds under the same conditions of concentration and time. All references cited herein are incorporated by reference. The present invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof and, accordingly, reference should be made to the appended claims, rather than to the foregoing specification, as indication the scope of the invention. WE CLAIM; 1. A substituted styryl benzylsulfone compound of the formula, having an E- configuration or a Z-configuration: (Formula Removed) wherein: (i) minimum three of R6, R7, R8, R9 and R10 are independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl, and the balance of said R6, R7, R8, R9 and R10 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano. carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; and (ii) R1, R2, R3, R4 and R5 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl. phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy), and trifluoromethyl; or a pharmaceutically acceptable salt thereof. 2. A compound as claimed in claim 1 wherein R1, R2, R3, R4 and R5 are halogen, same or different, and R6, R7, R8, R9 and R10 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl and C1-C6 alkoxy. 3. A compound as claimed in claim 2 wherein R8 is halogen or C1-C3 alkoxy. 4. A compound as claimed in claim 1 wherein R3 is C1-C6 alkoxy, minimum two of R1, R2, R4 and R5 are C1-C6 alkoxy, and the remainder of R1, R2, R4 and R5 arc hydrogen. 5. The compound as claimed in claim 1 which is (E)-2,3,4-trifluorostyryl-4-fluorobenzylsulfone. 6. The compound as claimed in claim 1 which is (E)-2,3,4-trifluorostyryl-4-chlorobenzylsulfone. 7. A compound as claimed in claim 1 wherein R6, R7, R8, R9 and R10 arc halogen, same or different, and R1, R2, R3, R4 and R5 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl and C1-C6 alkoxy. 8. A compound as claimed in claim 7 wherein R3 is halogen or C1-C3 alkoxy. 9. The compound as claimed in claim 8 which is (E)-2,3,4,5,6-pentafluorostyryl-4-fluorobenzylsulfone. 10. The compound as claimed in claim 9 which is (E)-2,3,4,5,6-pentafluorostyryl-4-chlorobenzylsulfone. 11. The compound as claimed in claim 9 which is (E)-2,3,4,5,6-pentafluorostyryl-4-bromobenzylsulfone. 12. The compound as claimed in claim 9 which is (E)-2,3,4,5,6-pentafluorostyryl-3,4-dichlorobenzylsulfone 13. The compound as claimed in claim 9 which is (E)-2,3,4,5,6-pentafluorostyryl-4-iodobenzylsulfone. 14. A compound as claimed in claim 1 wherein R3 is selected from the group consisting of halogen, nitro, cyano, C1-C6 alkyl, C1-C6 alkoxy, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; and R1, R2. R4 and R5 are hydrogen; or a pharmaceutically acceptable salt thereof. 15. A compound as claimed in claim 14 wherein the compound is (E)-3,4-dimethoxy-6-nitrostyryl-4-methoxybenzylsulfone. 16. A compound as claimed in claim 14 of the formula: (Formula Removed) wherein: R3 and R8 are independently selected from the group consisting of halogen, C1-C6 alkoxy, nitro, cyano, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; and R6 and R10 are independently selected from the group consisting of C1-C6 alkoxy. hydroxyl, phosphonato, amino, sulfamyl, acetoxy and dimethylamino(C2-C6 alkoxy); or a pharmaceutically acceptable salt thereof. 17. The compound as claimed in claim 16 wherein the compound is (E)-2-hydroxy-4,6-dimethoxystyryl-4-methoxybenzylsulfone, or a pharmaceutically acceptable salt thereof. 18. The compound as claimed in claim 16 wherein the compound is (E)-2-hydroxy-4,6-dimethoxystyryl-4-chlorobenzylsulfone, or a pharmaceutically acceptable salt thereof. 19. A compound as claimed in claim 16 wherein R6 and R10 are C1-C6 alkoxy. 20. The compound as claimed in claim 19 which is (E)-2,6-dimethoxy-4- hydroxystyryl-4-methoxybenzylsulfone, or a pharmaceutically acceptable salt thereof. 21. A compound as claimed in claim 16, wherein R3 and R8 are independently selected from the group consisting of halogen and C1-C6 alkoxy. 22. The compound as claimed in claim 21 wherein the compound is (E)-2,6-dimethoxy-4-fluorostyryl-4-methoxybenzylsulfone. 23. The compound as claimed in claim 21 wherein the compound is (E)-2,4.6-trimethoxystyryl-4-chlorobenzylsulfone. 24. The compound as claimed in claim 21 wherein the compound is (E)-2.6-dimethoxy-4-fluorostyryl-4-chlorobenzylsulfone. 25. The compound as claimed in claim 21 wherein the compound is (E)-2,4,6-trimefhoxystyryl-4-bromobenzylsulfone. 26. The compound as claimed in claim 21 wherein the compound is (E)-2.6-dimethoxy-4-fluorostyryl-4-bromobenzylsulfone. 27. A compound as claimed in claim 21 wherein R3 and R8 are C1-C6 alkoxy. same or different. 28. The compound as claimed in claim 27 wherein the compound is (E)-2,4,6-trimethoxystyryl-4-methoxybenzylsulfone. 29. A compound as claimed in claim 1 wherein R3 is a halogen, R1, R2, R4 and R5 are hydrogen, and R6, R7, R8, R9 and R10 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy. nitro, cyano, carboxyl. hydroxyl and trifluoromethyl; or a pharmaceutically acceptable salt thereof. 30. A compound as claimed in claim 29 wherein R6, R7, R8, R9 and R10 arc selected from the group consisting of hydrogen, halogen and C1-C6 alkoxy. 31. A compound as claimed in claim 30 wherein minimum two of R6, R7, R8- R9 and R10 are selected from C1-C6 alkoxy. 32. A compound as claimed in claim 31 wherein the C1-C6 alkoxy groups are methoxy groups. 33. A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof as claimed in any of claims 1 to 32 and a pharmaceutically acceptable carrier. 34. A compound or a pharmaceutically acceptable salt thereof as claimed in any of claims 1 to 32, for treatment of a proliferative disorder selected from the group consisting of cancer, hemangiomatosis in new born, secondary progressive multiple sclerosis, chronic progressive myelodegenerative disease, neurofibromatosis, ganglioneuromatosis, keloid formation, Pagets Disease of the bone, fibrocystic disease of the breast, Peronies and Duputren's fibrosis, restenosis and cirrhosis.

Full Text

Field of the Invention
The invention relates to compositions and methods for the treatment of cancer and other proliferate disorders.
Background of the Invention
Extracellular signals received at transmembrane receptors are relayed into the cells by the signal transduction pathways (Pelech et a/., Science 257:1335 (1992)) which have been implicated in a wide array of physiological processes such as induction of cell proliferation, differentiation or apoptosis (Davis et a/., J. Biol. Chem. 268:14553 (1993)). The Mitogen Activated Protein Kinase (MARK) cascade is a major signaling system by which cells transduce extracellular cues into intracellular responses (Nishida et a/., Trends Biochem. Sci. 18:128 (1993); Blumer et a/., Trends Biochem. Sci. 19:236 (1994)). Many steps of this cascade are conserved, and homologous for MAP kinases have been discovered in different species.
In mammalian cells, the Extracellular-Signal-Regulated Kinases (ERKs), ERK-1 and ERK-2 are the archetypal and best-studied members of the MAPK family, which all have the unique feature of being activated by
phosphorylation on threonine and tyrosine residues by an upstream dual specificity kinase (Posada et a/., Science 255:212 (1992); Biggs III et a/., Proc. Natl. Acad. Sci. USA 89:6295 (1992); Garner et a/., Genes Dev. 6:1280 (1992)).
Recent studies have identified an additional subgroup of MAPKs, known as c-Jun NH2-terminal kinases 1 and 2 (JNK-1 and JNK-2), that have different substrate specificities and are regulated by different stimuli (Hibi et a/., Genes Dev. 7:2135 (1993)). JNKs are members of the class of stress-activated protein kinases (SPKs). JNKs have been shown to be activated by treatment of cells with UV radiation, pro-inflammatory cytokines and environmental stress (Derij'ard et a/., Cell 1025 (1994)). The activated JNK binds to the amino terminus of the c-Jun protein and increases the protein's transcriptional activity by phosphorylating it at ser63 and ser73 (Adler et a/., Proc. Natl. Acad. Sci. USA 89:5341 (1992); Kwokera/., Nature 370:223 (1994)).
Analysis of the deduced primary sequence of the JNKs indicates that they are distantly related to ERKs (Davis, Trends Biochem. Sci. 19:470 (1994)). Both ERKs and JNKs are phosphorylated on Tyr and Thr in response to external stimuli resulting in their activation (Davis, Trends Biochem. Sci. 19:470 (1994)). The phosphorylation (Thr and Tyr) sites, which play a critical role in their activation are conserved between ERKs and JNKs (Davis, Trends Biochem. Sci. 19:470 (1994)). However, these sites of phosphorylation are located within distinct dual phosphorylation motifs: Thr-Pro-Tyr (JNK) and Thr-Glu-Tyr (ERK). Phosphorylation of MAPKs and JNKs by an external signal often involves the activation of protein tyrosine kinases (PTKs) (Gille et a/., Nature 358:414 (1992)), which constitute a large family, of proteins encompassing several growth factor receptors and other signal transducing molecules.
Protein tyrosine kinases are enzymes which catalyze a well defined chemical reaction: the phosphorylation of a tyrosine residue (Hunter et a/., Annu Rev Biochem 54:897 (1985)). Receptor tyrosine kinases in particular are attractive targets for drug design since blockers for the substrate domain of these kinases is likely to yield an effective and selective antiproliferative agent. The potential use of protein tyrosine kinase blockers as antiproliferative agents was

recognized as early as 1981, when quercetin was suggested as a PTK blocker (Graziani et a/., Eur. J. Biochem. 135:583-589 (1983)).
The best understood MARK pathway involves extracellular signal-regulated kinases which constitute the Ras/Raf/MEK/ERK kinase cascade (Boudewijn et a/., Trends Biochem. Sci. 20, 18 (1995)). Once this pathway is activated by different stimuli, MARK phosphorylates a variety of proteins including several transcription factors which translocate into the nucleus and activate gene transcription. Negative regulation of this pathway could arrest the cascade of these events.
What are needed are new anticancer chemotherapeutic agents which target receptor tyrosine kinases and which arrest the Ras/Raf/MEK/ERK kinase cascade. Oncoproteins in general, and signal transducing proteins in particular, are likely to be more selective targets for chemotherapy because they represent a subclass of proteins whose activities are essential for cell proliferation, and because their activities are greatly amplified in proliferative diseases.
What is also needed are new cell antiproliferative agents, and anticancer therapeutics in particular, which are highly selective in the killing of proliferating cells such as tumor cells, but not normal cells.
Summary of the Invention
It is an object of the invention to provide compounds, compositions and methods for the treatment of cancer and other proliferative diseases. The biologically active compounds are.in the form of styryl benzylsulfones.
It is an object of the invention to provide compounds which are selective in killing tumor cells but not normal cells.
According to one embodiment of the invention, novel compounds are provided according to formula I
(Formula Removed)

wherein
(a) (i) at least three of R1, R2, R3, R4 and R5 are independently
selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro,
cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy,
dimethylamino(C2-C6 alkoxy) and trifluoromethyl, and the balance of said R1, R2, R3, R4 and R5
are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; and
(ii) R6, R7, R8, R9 and R10 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; or
(b) (i) at least three of R6, R7, R8, R9 and R10 are independently
selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro,
cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy,
dimethylamino(C2-C6 alkoxy) and trifluoromethyl, and the balance of said R6, R7, R8, R9
and R10
are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; and
(ii) R1, R2, R3, R4 and R5 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl;

or a pharmaceutically acceptable salt thereof.
The styryl benzylsulfones are characterized by cis-trans isomerism resulting from the presence of a double bond. The compounds are named according to the Cahn-lngold-Prelog system, the IUPAC 1974 Recommendations, Section E: Stereochemistry, in Nomenclature of Organic Chemistry, John Wiley & Sons, Inc., New York, NY, 4th ed, 1992, p. 127-138. Steric relations around a double bond are designated as "Z" or "E". Both configurations are included in the scope of the present invention.
(Formula Removed)
According to one embodiment, the benzyl nucleus, that is, the ring system containing R1 through R5 is at least trisubstituted. Thus, in formula I,
(i) at least three of R1, R2, R3, R4 and R5 are independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl, and the balance of said R1, R2, R3,
R4 and R5
are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; and
(ii) R6, R7, R8, R9 and R10 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl.
According to a preferred sub-embodiment of the aforesaid E-configuration compounds, the benzyl nucleus is penta-substituted with halogen, that is, R1, R2, R3, R4 and R5 are halogen, same or different, and R6, R7, R8, R9
and R10
are independently selected from the group consisting of hydrogen,

halogen, C1-C6 alkyl and C1-C6 alkoxy. In some embodiments, R8 is halogen or C1-C6 alkoxy.
According to another preferred sub-embodiment of the aforesaid E-configuration compounds, R3 is C1-C6 alkoxy, at least two of R1, R2, R3, R4 and R5 are C1-C6 alkoxy, and the remainder of R1, R2, R3, R4 and R5 are hydrogen.
According to another embodiment, the styryl nucleus, that is, the ring system containing R6 through RIO, is at least trisubstituted. Thus, in formula I, (i) at least three of R6, R7, R8, R9 and RIO are independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl, and the balance of said R6, R7, R8, R9
and RIO
are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; and
(ii) R1, R2, R3, R4 and R5are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy), and trifluoromethyl.
According to a preferred sub-embodiment, the compounds have the E-configuration and the styryl nucleus is penta-substituted with halogen, that is, R6, R7, R8, R9 and RIO are halogen, same or different. R1, R2, R3, R4 and R5 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl and C1-C6 alkoxy. In. some such embodiments, R3 is halogen or C1-C6 alkoxy.
According to another embodiment, a compound has the E-configuration and is mono-substituted at the 4-position on the benzyl nucleus. R3 is selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; andR1, R2, R3, R4 and R5 are hydrogen. At least three of R6, R7, R8, R9 and RIO are independently selected from the group consisting of

halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl, and the balance of said R6, R7, R8, R9 and RIO are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl. In some embodiments, R3 is halogen and R6, R7, R8, R9 and RIO are preferably selected from hydrogen, halogen and C1-C6 alkoxy, provided that at least three of R6, R7, R8, R9 and RIO
.are halogen, C1-C6 alkoxy, or combination thereof.
In a preferred sub-embodiment of 4-position substitution on the benzyl nucleus, the compounds have the formula IV:
(Formula Removed)

wherein R3 and R8 are independently selected from the group consisting of halogen, C1-C6 alkoxy, nitro, cyano, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl. R6 and R1o are independently selected from the group consisting of C1-C6 alkoxy, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy); or a pharmaceutically acceptable salt thereof. In some embodiments, R3 and R8 are independently selected from the group consisting of halogen and C1-C6 alkoxy. R6 and RIO are preferably. C1-C6 alkoxy, more preferably C1-C3 alkoxy. In some embodiments, R3, R6, R8, and RIO are C1-C6 alkoxy, preferably C1-C3 alkoxy. The various alkoxy groups may be the same or different.
According to another embodiment, the compound has the Z-configuration, and the benzyl nucleus, that is, the ring system containing Rj through R5, is at least trisubstituted. Thus, in formula I,
(i) at least three of RI, R2, R3, R4 and R5 are independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro,

cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl, and the balance of said RI, R2, R3, R4and R5 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; and
(ii) R6, R7, R8, R9 and RIO are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl.
In some such embodiments of Z configuration compound, the benzyl nucleus is trisubstituted with C1-C6 alkoxy, that is, two of R1, R2, R3,R4 and R5 are hydrogen and three of R1, R2, R3,R4 and R5 are C1-C6 alkoxy, preferably, methoxy. In such compounds, the styryl nucleus is unsubstituted, or from mono-substituted up to penta-substituted, particularly penta-substitution with halogen.
According to another embodiment, the compound has the Z configuration and the styryl nucleus, that is, the ring system containing R6 through RIO, is at least trisubstituted. Thus, in formula I,
(i) at least three of R6, R7, R8, R9 and RIO are independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl, and the balance of said R6, R7, R8, R9 and RIO
are independently selected from the group consisting of hydrogen, .halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; and
(ii) R1, R2, R3,R4 and R5 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy), and trifluoromethyl.

According to one such embodiment of Z configuration compound, the styryl nucleus is penta-substituted with halogen. R6, R7, R8, R9 and R10 are halogen, same or different, but preferably fluorine. In some such embodiments where the styryl nucleus is penta-substituted, R1, R2, R3,R4 and R5 are independently selected from the group consisting of hydrogen, halogen C1-C6 alkyl and C1-C6 alkoxy. In some such embodiments, the benzyl nucleus is trisubstituted with C1-C6 alkoxy, that is, two of R1, R2, R3,R4 and R5 are hydrogen and three of R1, R2, R3,R4 and R5 are C1-C6 alkoxy, preferably methoxy. In other such embodiments, the benzyl nucleus is mono-substituted at the 4-position, that is, R1, R2, R3,R4 and R5 are hydrogen, and R3 is other than hydrogen. In some such mono-substitution sub-embodiments, R3 is C1-C6 alkoxy, preferably methoxy, or halogen.
According to other embodiments of Z configuration compound, the benzyl nucleus is monosubstituted with halogen, particularly at the 4-position, and the styryl nucleus is at least trisubstituted, preferably with halogen.
According to one embodiment of Z configuration compound, R1, R2, R3,R4 and R5
are halogen, same or different, and R6, R7, R8, R9 and R10 are independently selected from the group consisting of hydrogen, halogen, C1-C3 alkyl and C1-C3 alkoxy.
According to other embodiments, processes for preparing compounds according to formula I are provided. In one such embodiment, the compound has the E configuration. The compound is prepared by condensing a compound of formula III
(Formula Removed)
with a compound of formula VI:

(Formula Removed)

wherein
(a) (i) at least three of R1, R2, R3, R4 and R5are independently
selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro,
cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy,
dimethylamino(C2-C6 alkoxy) and trifluoromethyl, and the balance of said R1, R2, R3, R4 and R5
are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; and
(ii) R6, R7, R8, R9 and R10 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; or
(b) (i) at least three of R6, R7, R8, R9 and R10 are independently
selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro,
cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy,
dimethylamino(C2-C6 alkoxy) and trifluoromethyl, and the balance of said R6, R7,
R8, R9 and RIO are independently selected from the group consisting of hydrogen,
halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl,
phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and
trifluoromethyl; and
(ii) R1, R2, R3, R4 and R5 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl.
The formula III compound may be prepared, for example, by reacting sodium glycollate with a benzyl chloride compound of the formula:
(Formula Removed)

to form a benzylthioacetic acid compound of the formula:
(Formula Removed)
which is then oxidized to form a compound of formula III, wherein RI through R5are defined as above.
Alternatively, the benzylthioacetic acid intermediate is prepared by reacting a compound of the formula HSCH2COOR where R is C1-C6 alkyl with the aforementioned benzyl chloride compound to form a compound of formula II:

(Formula Removed)
wherein R1 is C1-C6 alkyl, which is then converted to the corresponding benzylthioacetic acid compound by alkaline or acid hydrolysis.
A process for preparing compounds according to formula I having the Z configuration is provided. A sodium benzylthiolate of the formula:
(Formula Removed)
is reacted with a phenylacetylene of the formula:

to form a Z-styryl benzylsulfide of formula la:
(Formula Removed)
wherein RI through R10 are defined as above. The Z-styryl benzylsulfide is then oxidized to form a compound according to formula I having the Z-configuration
The term "alkyl", by itself or as part of another substituent means, unless otherwise stated, a straight or branched chain hydrocarbon radical, including di- and multi-radicals, having the number of carbon atoms designated (i.e. C1-C6 means one to six carbons) and includes straight or branched chain groups. Most preferred is C1-C3 alkyl, particularly ethyl and methyl.
The term "alkoxy" employed alone or in combination with other terms means, unless otherwise stated, an alkyl group having the designated number of carbon atoms, as defined above, connected to the rest of the molecule via an oxygen atom, such as, for example, methoxy, ethoxy, 1-propoxy, 2-propoxy and the higher homologs and isomers. Preferred are C1-C3 alkoxy, particularly ethoxy and methoxy.
By "dimethylamino (C2-C6 alkoxy)" is meant (CH3)2N(CH2)nO-wherein n is from 2 to 6. Preferably, n is 2 or 3. Most preferably, n is 2, that is, the group is the dimethylaminoethoxy group: (CH3)2NCH2CH2O-.
By "halogen" is meant fluorine, chlorine, bromine or iodine.
By "phosphonato" is meant the group -PO (OH)2.
By "sulfamyl" is meant the group -SO2NH2.
Where a substituent on the benzyl or styryl nucleus is an alkyl or alkoxy group, the carbon chain may be branched or straight, with straight being

preferred. Preferably, the alkyl and alkoxy groups comprise C1-C3 alkyl and C1-C3 alkoxy, most preferably methyl and methoxy.
By "substituted" is meant that an atom or group of atoms has replaced hydrogen as the substituent attached to another group.
By "subject" is meant an animal or a human being.
A pharmaceutical composition is also provided comprising a pharmaceutically acceptable carrier and one or more compounds of formula I above, or a pharmaceutically acceptable salt of such compound.
According to another embodiment of the invention, a method of treating an individual for a proliferative disorder, particularly cancer, is provided, comprising administering to said individual an effective amount of a compound according to formula I, or a pharmaceutically acceptable salt of such compound, alone or in combination with a pharmaceutically acceptable carrier.
In another embodiment of the invention, a method of inhibiting growth of tumor cells in an individual afflicted with cancer is provided comprising administering to said individual an effective amount of a compound according to formula I, or a pharmaceutically acceptable salt of such compound, alone or in combination with a pharmaceutically acceptable carrier.
In another embodiment, a method of inducing apoptosis of cancer cells, more preferably tumor cells, in an individual afflicted with cancer is provided, comprising administering to said individual an effective amount of a compound according to formula I, or a pharmaceutically acceptable salt of such compound, alone or in combination with a pharmaceutically acceptable carrier.
In another embodiment, novel compounds are provided which are useful as intermediates in preparing the compounds of formula I. The intermediates comprise the compounds of formulae II and III:
(Formula Removed)

wherein R is hydrogen or C1-C6 alkyl; and at least three of R1, R2, R3, R4 and R5 are independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl, and the balance of said R1, R2, R3, R4 and R5 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl.
According to another embodiment, novel intermediates useful in preparing the compounds of formula I comprise the compounds of formula V
(Formula Removed)
wherein:
(Formula Removed)
R 1is H or C1-C6 .alkyl; and
X and are Y independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy), and trifluoromethyl;
provided: when Y is hydrogen, X may not be hydrogen, 4-chloro, 4-bromo, 4-fluoro or 4-alkoxy.

In one embodiment, X and Y are as defined as above, with the further provision that when Y is hydrogen, X may not be 4-trifluoromethyl, 4-nitro or 4-cyano; and when X is 4-chloro, Y may not be 2-chloro or 3-chloro.
According to a preferred embodiment, intermediates are provided according to formula V wherein Y is hydrogen and X is selected from the group consisting of 4-hydroxy, 4-amino and 4-sulfamyl.
Detailed Description of the Invention
According to the present invention, certain highly substituted styryl benzylsulfone derivatives and pharmaceutically acceptable salts thereof selectively kill various tumor cell types without killing normal cells.
At least one of the benzyl or styryl aromatic nuclei is at least tri-substituted. By "substituted" in this context means that an atom or group of atoms has replaced hydrogen as the substituent attached to an aromatic ring carbon atom.
According to certain embodiments, the benzyl and/or styryl aromatic nuclei are tri-substituted, that is, only two of RI through R5 are hydrogen, and/or only two of R6 through R1o are hydrogen. Representative combinations of substituents are set forth in Table 1
(Table Removed)
Table 1: Tri-Substitution

According to certain embodiments, the benzyl and/or styryl aromatic nuclei are tetra-substituted, that is, only one of R1 through R5 is hydrogen, and/or only one of R6 through R10 is hydrogen. Representative combinations of substituents are set forth in Table 2:
Table 2: Tetra-Substitution

(Table Removed)
According to other embodiments, the benzyl and/or styryl aromatic nuclei are penta-substituted, preferably with halogen, most preferably with the same halogen, for example, penta-substitution with fluorine.

The pattern of substitution with respect to the position of the substituents on the benzyl or styryl nuclei may comprise any pattern of substitution. For example, tri-substitution may comprise substitution at positions 2, 3 and 4, positions 2, 4 and 5, or positions 2, 4 and 6, for example. Likewise, the pattern of tetra-substitution may comprise, for example, substitution at positions 2, 3, 4 and 5, or positions 2, 3, 5 and 6.
According to certain preferred embodiments, the 4-position of the benzyl and/or styryl nuclei is substituted, that is, R3 and/or R8 are other than hydrogen. Preferably, R3 and/or R8are halogen or C1-C6 alkoxy.
According to one such embodiment of 4-position substitution, the benzyl nucleus is mono-substituted at its 4 position. R3is selected from the group consisting of halogen, C1-C6 alkoxy, nitro, cyano hydroxyl, phosphonato, amino, sulfamyl, acetoxy, and dimethylamino(C2-C6 alkoxy) and trifluoromethyl; RI, R2, R4 and R5 are hydrogen; and R6, R7, R8, R9 and R1o are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl, wherein at least three of. R6, R7, R8, R9 and R1o
are other than hydrogen. Particularly preferred are compounds according to formula IV, and pharmaceutically acceptable salts thereof:
(Formula Removed)
wherein R3 and R8 are independently selected from the group consisting of halogen, C1-C6 alkoxy, nitro, cyano, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl. R6 and R10 are independently selected from the group consisting of C1-C6 alkoxy, hydroxyl, phosphonato, amino, sulfamyl, acetoxy and dimethylamino(C2-C6 alkoxy). In some embodiments, R3 and R8 are independently selected from the group

consisting of halogen and C1-C6 alkoxy. R6 and RIO are preferably C1-C6 alkoxy, more preferably C1-C3 alkoxy. In some embodiments, R3, R6, R8, and R10 are C1-C6 alkoxy, preferably C1-C3 alkoxy.
According to another such embodiment of 4-position substitution in formula I, R3 is C1-C6 alkoxy; and two of R1, R2, R4 and R5 are also C1-C6 alkoxy, with the remainder of R1, R2, R4 and R5 being hydrogen, that is, the benzyl nucleus is trisubstituted with C1-C6 alkoxy groups. R6, R7, R8, R9 and R1oare independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl.
In each of the above embodiments containing alkoxy substituents on the benzyl and/or styryl nucleus, the alkoxy group is preferably a C1-C3 alkoxy group, must preferably methoxy.
Without wishing to be bound by any theory, it is believed that the compounds affect the MARK signal transduction pathway, thereby affecting tumor cell growth and viability. This cell growth inhibition is associated with regulation of the ERK and JNK types of MAPK. Without wishing to be bound by any theory, the styryl sulfones of the present invention may block the phosphorylating capacity of ERK-2.
The compounds of the invention have been shown to inhibit the proliferation of tumor cells by inducing cell death. The compounds are believed effective against a broad range of tumor types, including but not limited to the following: breast, prostate, ovarian, lung, colorectal, brain (i.e., glioma) and renal. .The compounds are. also believed effective against leukemic .cells. The compounds do not kill normal cells in concentrations at which tumor cells are killed.
The compounds are also believed useful in the treatment of non-cancer proliferative disorders, including but not limited to the following: hemangiomatosis in new born, secondary progressive multiple sclerosis, chronic progressive myelodegenerative disease, neurofibromatosis, ganglioneuromatosis,

keloid formation, Paget's disease of the bone, fibrocystic disease of the breast, Peyronie's fibrosis, and Dupuytren's fibrosis, restenosis and cirrhosis.
Treatment of this broad range of tumor cells with the styryl benzylsulfone compounds of the invention leads to inhibition of cell proliferation and induction of apoptotic cell death.
Tumor cells treated with the compounds of the invention accumulate in the G2/M phase of the cell cycle. As the cells exit the G2/M phase, they appear to undergo apoptosis. Treatment of normal cells with the styryl sulfones does not result in apoptosis.
(E)-Styryl benzylsulfones may be prepared by Knoevenagel condensation of aromatic aldehydes with benzylsulfonyl acetic acids. The procedure is described by Reddy et a/., Acta. Chim. Hung. 115:269-71 (1984); Reddy et a/., Sulfur Letters 13:83-90 (1991); Reddy et a/., Synthesis No. 4, 322-323 (1984); and Reddy et a/., Sulfur Letters 7:43-48 (1987), the entire disclosures of which are incorporated herein by reference.
According to the Scheme 1 below, Ra and Rb each represent from zero to five substituents on the depicted aromatic nucleus. The benzyl thioacetic acid B is formed by the reaction of sodium thioglycollate and a benzyl chloride A. The benzyl thioacetic acid B is then oxidized with 30% hydrogen peroxide to give a corresponding benzylsulfonyl acetic acid C. Condensation of the benzylsulfonyl acetic acid C with an aromatic aldehyde D via a Knoevenagel reaction in the presence of benzylamine and glacial acetic acid yields the desired (E)-styryl benzylsulfone E.
(Formula Removed)
The following is a more detailed two-part synthesis procedure for preparing (E)-styryl benzylsulfones according to the above scheme.
General Procedure 1: Synthesis (E)-Styryl benzylsulfones
Part A. To a solution of (8g, 0.2 mol) sodium hydroxide in methanol (200 ml), thioglycollic acid (0.1 mol) is added slowly and the precipitate formed is dissolved by stirring the contents of the flask. Then an appropriately substituted or unsubstituted benzyl chloride (0.1 mol) is added stepwise and the reaction mixture is refluxed for 2-3 hours. The cooled contents are poured onto crushed ice and neutralized with dilute hydrochloric acid (200 ml). The resulting corresponding benzylthioacetic acid (0.1 mol) is subjected to oxidation with 30% hydrogen peroxide (0.12 mol) in glacial acetic acid (125 ml) by refluxing for 1 hour. The contents are cooled and poured onto crushed ice. The separated solid is recrystalized from hot water to give the corresponding pure benzylsulfonylacetic acid.
Part B. A mixture of the benzylsulfonyl acetic acid (10 mmol), an appropriately substituted or unsubstituted aromatic aldehyde (10 mmol), and benzylamine (200 ml) in glacial acetic acid (12 ml) is refluxed for 2-3 hours. The contents are cooled and treated with cold ether (50 ml). Any product precipitated out is separated by filtration. The filtrate is diluted with more ether and washed

successively with a saturated solution of sodium bicarbonate (20 ml), sodium bisulfite (20 ml), dilute hydrochloric acid (20 ml) and finally with water (35 ml). Evaporation of the dried ethereal layer yields styryl benzylsulfones as a solid material.
According to an alternative to Part A, the appropriate benzylsulfonylacetic acids may be generated by substituting a thioglycollate HSChfeCOOR for thioglycollic acid, where R is an alkyl group, typically C1-C6 alkyl. This leads to the formation of the alkylbenzylthioacetate intermediate (F),
(Formula Removed)

which is then converted to the corresponding benzyl thioacetic acid B by alkaline or acid hydrolysis.
(Z)-Styryl benzylsulfones are prepared by the nucleophilic addition of the appropriate thiol to substituted phenylacetylene with subsequent oxidation of the resulting sulfide by hydrogen peroxide to yield the Z-styryl benzylsulfone. The procedure is generally described by Reddy et a/., Sulfur Letters 13:83-90 (1991), the entire disclosure of which is incorporated herein as a reference.
In the first phase of the synthesis, a substituted or unsubstitued sodium benzylthiolate, prepared from an appropriate substituted or unsubstitued sodium benzyl mercaptan, is allowed to react with the appropriate substituted , phenylacetylene forming the pure Z-isomer of the corresponding substituted (Z)-styryl benzylsulfide in good yield. In the second step of the synthesis, the substituted (Z)-styryl benzylsulfide intermediate is oxidized to the corresponding sulfone in the pure Z- isomeric form by treatment with an oxidizing agent, such as hydrogen peroxide.
The following is a more detailed two-part synthesis procedure for preparing the substituted (Z)-styryl benzylsulfones. It may be appreciated that at

least one of the starting styrene and sodium benzyl mercaptan are at least trisubstituted, in order to form compounds according to formula I.
General Procedure 2: Synthesis of substituted (Z)-styryl benzylsulfones.
A. To a cooled stirred solution (40°C) of a substituted or unsubstituted
styrene (0.5 mol) in chloroform (200 ml) is added dropwise a solution of bromine
(0.5 mol) in chloroform (100 ml). After the addition is complete, the contents of
the flask are stirred for an additional 30 minutes. Removal of chloroform in
rotavapor yields a crystalline solid of a 1,2-dibromoaryl ethane.
B. A solution of potassium hydroxide (85 g) in rectified spirit (400 ml) is
cooled to room temperature (25°C) and the above 1,2-dibromoaryl ethane (0.33
mol) is added in portions to control the exothermic reaction. After the addition is
complete, the reaction mixture is heated to reflux for 6 hours. The contents are
then cooled and poured into water (1000 ml). The separated substituted or
unsubstituted phenylacetylene is purified either by distillation (in case of liquids) or
recrystallization (In case of solids).
C. To a refluxing methanolic solution of a substituted or unsubstituted
sodium benzylthiolate prepared from 460 mg (0.02g atom) of (i) sodium, (ii)
substituted or unsubstituted sodium benzyl mercaptan (0.02 mol) and (iii) 80 ml of
absolute methanol, is added a freshly distilled substituted or unsubstituted
phenylacetylene. The mixture is refluxed for 20 hours, cooled and then poured on
crushed ice. The crude product is filtered, dried and recrystallized from methanol
or aqueous methanol to yield pure substituted (Z)-styryl benzylsulfide.
D. An ice cold solution of a substituted (Z)-styryl benzylsulfide (3 g) in
30 ml of glacial acetic acid is treated with 7.5 ml of 30% hydrogen peroxide. The
reaction mixture is refluxed for 1 hour and poured onto crushed ice. The solid
separated is filtered, dried and recrystallized from 2-propanol to yield a pure
substituted (Z)-styryl benzylsulfone. The purity of the compound is ascertained by
TLC and geometrical configuration is assigned by IR and NMR spectral data.
The benzyl thioacetic acid B, benzylsulfonyl acetic acid C, and alkylbenzylthioacetate (F) are novel intermediates which form another aspect of the invention. Accordingly, intermediate compounds useful in the synthesis of the substituted benzylstyryl sulfones comprise the substituted benzylthioacetic acids and esters of formulae II, and the substituted benzylsulfonyl acetic acids of formula III,
(Formula Removed)
wherein:
R1isHorC1-C6alkyl;
at least three of R1, R2, R4 and R5 are independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl, and the balance of said R1, R2, R4 and R5 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl.
According to preferred embodiments of the intermediates of formulae II and III, at least three of R1, R2, R4 and R5 are independently selected from the group consisting of halogen, C1-C6 alkyl and C1-C6 alkoxy, and the balance of saidR1, R2, R4 and R5 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy. C1-C3 alkyl and C1-C3 alkoxy are the preferred alkyl and alkoxy substituents, with methyl and methoxy being most preferred. According of other preferred embodiments, all of R1, R2, R3, R4 and R5 are halogen, preferably the same halogen, or all are C1-C6 alkoxy, most preferably C1-C3 alkoxy, most preferably methoxy.
Other novel intermediates useful in preparing the compounds of formula I comprise the compounds of formulae V

(Formula Removed)
wherein:
(Formula Removed)
R1is H orC1-C6alkyl;and
X and are Y independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy), and trifluoromethyl;
provided:
when Y is hydrogen, X may not be hydrogen, 4-chloro, 4-
bromo, 4-fluoro or 4-alkoxy.
In one embodiment, X and Y are as defined as above, with the further provision that
when Y is hydrogen, X may not be 4-trifluoromethyl, 4-nitro or
4-cyano; and
when X is 4-chloro, Y may not be 2-chloro or 3-chloro.
According to a preferred embodiment, intermediates are provided according to formula V wherein Y is hydrogen and X is selected from the group consisting of 4-hydroxy, 4-amino and 4-sulfamyl.
The intermediates may be prepared according to General procedure 1, Part A, above.
Representative intermediates prepared according to the present invention, and their respective melting points, include the following (ND = melting point not done):
2,4-dichlorobenzylthioacetic acid, 69-71 °C;
2,4-dichlorobenzylsulfonylacetic acid, 178-180°C;
4-iodobenzylthioacetic acid, 79-81 °C;
4-iodobenzylsulfonylacetic acid 193-196°C;
2-methoxybenzylthioacetic acid, liquid;
2-methoxybenzylsulfonylacetic acid, liquid;
2,4-dimethoxy benzylthioacetic acid, ND;
2,4-dimethoxybenzylsulfonylacetic acid, ND;
4-cyanobenzylthioacetic acid, 80-82°C;
4-cyanobenzylsulfonylacetic acid, 211-213°C;
4-trifluoromethylbenzylthiolacetic acid, ND;
4-trifluoromethylbenzylsulfonylacetic acid, 162-164°C;
2,3,4-trimethoxybenzylthioacetic acid, liquid;
2,3,4-trimethoxybenzylsulfonylacetic acid, 140-144°C;
3,4,5-trimethoxybenzylthioacetic acid, ND;
3,4,5-trimethoxybenzylsulfonylacetic acid, 165-167°C; 2,4,6-trimethoxybenzylthioacetic acid, ND;
2,4,6-trimethoxybenzylsulfonylacetic acid, ND;
2-nitro-4,5-dimethoxybenzylthioacetic acid, ND;
2-nitro-4,5-dimethoxybenzylsulfonylacetic acid, 137-140°C;
3,5-dimethoxybenzylthioacetic acid, liquid;
3,5-dimethoxybenzylsulfonylacetic acid, liquid;
2-methoxy-5-nitrobenzylthioacetic acid, liquid;
2-methoxy-5-nitrobenzylsulfonylacetic acid, 158-160°C;
4-hydroxybenzylthioacetic acid, ND;
4-hydroxybenzylsulfonylacetic acid, ND;
1,2,3,4,5-pentafluorobenzylthioaceticacid, 68-70°C; and

1,2,3,4,5-pentafluorobenzylsulfonylacetic acid, 108-110°C.
The present invention is also directed to isolated optical isomers of compounds according to formula I. Certain compounds may have one or more chiral centers. By "isolated" means a compound which has been substantially purified from the corresponding optical isomer(s) of the same formula. Preferably, the isolated isomer is at least about 80%, more preferably at least 90% pure, even more preferably at least 98% pure, most preferably at least about 99% pure, by weight. The present invention is meant to comprehend diastereomers as well as their racemic and resolved, enantiomerically pure forms and pharmaceutically acceptable salts thereof. Isolated optical isomers may be purified from racemic mixtures by well-known chiral separation techniques. According to one such method, a racemic mixture of a compound having the structure of formula I, or chiral intermediate thereof, is separated into 99% wt.% pure optical isomers by HPLC using a suitable chiral column, such as a member of the series of DAICEL CHIRALPAK family of columns (Daicel Chemical Industries, Ltd., Tokyo, Japan). The column is operated according to the manufacturer's instructions.
The styryl benzylsulfone compounds of the present invention may be derivatized with a chemical group to permit conjugation to a carrier molecule, for the purpose of raising antibodies to the styryl sulfones. Suitable derivatizing chemistries are well-known to those skilled in the art. Preferably, the derivative comprises a carboxylic acid derivative. The carrier may comprise any molecule sufficiently large to be capable of generating an immune response in an appropriate host animal. One such preferred carrier is keyhole limpet haemocyanin (KLH).
The compounds of the present invention may take the form or pharmaceutically acceptable salts. The term "pharmaceutically acceptable salts", embraces salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. The nature of the salt is not critical, provided that it is pharmaceutically-acceptable. Suitable pharmaceutically acceptable acid addition salts may be prepared from an inorganic acid or from an organic acid.

Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, example of which are formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzole, anthranilic, mesylic, 4-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, 2-hydroxyethanesulfonic, toluenesulfonic, sulfanilic, cyclohexylaminosulfonic, stearic, alginic, beta-hydroxybutyric, salicylic, galactaric and galacturonic acid. Suitable pharmaceutically acceptable base addition salts of compounds of formula I include metallic salts made from calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine. All of these salts may be prepared by conventional means from the corresponding compound of formula I by reacting, for example, the appropriate acid or base with the compound of formula I.
The compounds of the invention may be administered in the form of a pharmaceutical composition, in combination with a pharmaceutically acceptable carrier. The active ingredient in such formulations may comprise from 0.1 to 99.99 weight percent. By "pharmaceutically acceptable carrier" is meant any carrier, diluent or excipient which is compatible with the other ingredients of the formulation and not deleterious to the recipient.
The compounds of the invention may be administered to individuals (mammals, including animals and humans) afflicted with cancer.
The compounds are also useful in the treatment of non-cancer proliferative disorders, that is, proliferative disorders which are characterized by benign indications. Such disorders may also be known as "cytoproliferative" or "hyperproliferative" in that cells are made by the body at an atypically elevated rate. Such disorders include, but are not limited to, the following: hemangiomatosis in new born, secondary progressive multiple sclerosis, chronic

progressive myelodegenerative disease, neurofibromatosis, ganglioneuromatosis, keloid formation, Paget's disease of the bone, fibrocystic disease of the breast, Peyronie's fibrosis and Dupuytren's fibrosis, restenosis and cirrhosis.
The compounds may be administered by any route, including oral and parenteral administration. Parenteral administration includes, for example, intravenous, intramuscular, intraarterial, intraperitoneal, intranasal, rectal, intravaginal, intravesical (e.g., to the bladder), intradermal, topical or subcutaneous administration. Also contemplated within the scope of the invention is the instillation of drug in the body of the patient in a controlled formulation, with systemic or local release of the drug to occur at a later time. For example, the drug may localized in a depot for controlled release to the circulation, or for release to a local site of tumor growth.
The compounds of the invention may be administered in the form of a pharmaceutical composition, in combination with a pharmaceutically acceptable carrier. The active ingredient in such formulations may comprise from 0.1 to 99.99 weight percent. By "pharmaceutically acceptable carrier" is meant any carrier, diluent or excipient which is compatible with the other ingredients of the formulation and not deleterious to the recipient.
The active agent is preferably administered with a pharmaceutically acceptable carrier selected on the basis of the selected route of administration and standard pharmaceutical practice. The active agent may be formulated into dosage forms according to standard practices in the field of pharmaceutical preparations. See Alphonso Gennaro, ed., Remington's Pharmaceutical Sciences, 18th Ed., (1990) Mack Publishing Co., Easton, PA. Suitable dosage forms may comprise, for example, tablets, capsules, solutions, parenteral solutions, troches, suppositories, or suspensions.
For parenteral administration, the active agent may be mixed with a suitable carrier or diluent such as water, an oil (particularly a vegetable oil), ethanol, saline solution, aqueous dextrose (glucose) and related sugar solutions, glycerol, or a glycol such as propylene glycol or polyethylene glycol. Solutions for parenteral administration preferably contain a water soluble salt of the active

agent. Stabilizing agents, antioxidizing agents and preservatives may also be added. Suitable antioxidizing agents include sulfite, ascorbic acid, citric acid and its salts, and sodium EDTA. Suitable preservatives include benzalkonium chloride, methyl- or propyl-paraben, and chlorbutanol. The composition for parenteral administration may take the form of an aqueous or nonaqueous solution, dispersion, suspension or emulsion.
For oral administration, the active agent may be combined with one or more solid inactive ingredients for the preparation of tablets, capsules, pills, powders, granules or other suitable oral dosage forms. For example, the active agent may be combined with at least one excipient such as fillers, binders, humectants, disintegrating agents, solution retarders, absorption accelerators, wetting agents absorbents or lubricating agents. According to one tablet embodiment, the active agent may be combined with carboxymethylcellulose calcium, magnesium stearate, mannitol and starch, and then formed into tablets by conventional tableting methods.
The specific dose of compound according to the invention to obtain therapeutic benefit will, of course, be determined by the particular circumstances of the individual patient including, the size, weight, age and sex of the patient, the nature and stage of the disease, the aggressiveness of the disease, and the route of administration. For example, a daily dosage of from about 0.05 to about 50 mg/kg/day may be utilized. Higher or lower doses are also contemplated.
The practice of the invention is illustrated by the following non-limiting examples. . For each (E) configuration compound, the substituted benzylsulfonyl acetic acid was made according to Part A of General Procedure 1: Synthesis (E)-Styryl Benzylsulfones, above. Some of the styryl benzylsulfone compounds were recrystalized from 2-propanol and the purity was checked by thin layer chromatography. Each (Z) configuration compound is prepared by following General Procedure 2: Synthesis (Z)-Styryl Benzylsulfones, above. For brevity, only the principal reactants are listed in each example, it being understood that the principal reactants are made from precursors as set forth in the General
Procedure, and then combined under the conditions set forth in the General Procedure.
Example 1 (E)-2,3,4,5,6-Pentafluorostyryl-4-fluorobenzylsulfone
A solution of 4-fluorobenzylsulfonylacetic acid (10 mmol) and pentafluorobenzaldehyde (10mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 133-136°C, was obtained in 80% yield.
Example 2 (E)-2,3,4,5,6-Pentafluorostyryl-4-chlorobenzylsulfone
A solution of 4-chlorobenzylsulfonylacetic acid (10 mmol) and pentafluorobenzaldehyde (10mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 147-148°C, was obtained in 82% yield.
Example 3 (E)-2,3,4,5,6-Pentafluorostyryl-4-bromobenzylsulfone
A solution of 4-bromobenzylsulfonylacetic acid (10 mmol) and pentafluorobenzaldehyde (10mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 163-164°C, was obtained in 85% yield.
Example 4 (E)-4-Fluorostyryl-2,3,4,5,6-pentafluorobenzylsulfone
A solution of pentafluorobenzylsulfonylacetic acid (10 mmol) and 4-fluorobenzaldehyde (10mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 133-136°C, was obtained in 78% yield.

Example 5 (E)-4-Chlorostyryl-2,3,4,5,6-pentafluorobenzylsulfone
A solution of pentafluorobenzylsulfonylacetic acid (10 mmol) and 4-chlorobenzaldehyde (10mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 154-155°C, was obtained in 80% yield.
Example 6 (E)-4-Bromostyryl-2,3,4,5,6-pentafluorobenzylsulfone
A solution of pentafluorobenzylsulfonylacetic acid (10 mmol) and 4-bromobenzaldehyde (10mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 176-177°C, was obtained in 92% yield.
Example 7 (E)-2,3,4,5,6-Pentafluorostyryl-3,4-dichlorobenzylsulfone
A solution of 3,4-dichlorobenzylsulfonylacetic acid (10 mmol) and pentafluorobenzaldehyde (10mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 171-173°C, was obtained in 84% yield.
Example 8 (E)-2,3,4,5,6-Pentafluorostyryl-2,3,4,5,6-pentafluorobenzylsulfone
A solution of pentafluorobenzylsulfonylacetic acid (10 mmol) and pentafluorobenzaldehyde (10mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 137-139°C, was obtained in 84% yield.
Example 9 (E)-2,3,4,5,6-Pentafluorostyryl-4-iodobenzylsulfone
A solution of 4-iodobenzylsulfonylacetic acid (10 mmol) and pentafluorobenzaldehyde (10mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 178-181°C, was obtained in 51% yield.

Example 10 (E)-2-Hydroxy-3,5-dinitrostyryl-4-fluorobenzylsufone
A solution of 4-fluorobenzylsulfonylacetic acid (10mmol) and 2-hydroxy-3,5-dinitrobenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 211-212°C, was obtained in 54% yield.
Example 11 (E)-2-Hydroxy-3,5-dinitrostyryl-4-bromobenzylsufone
A solution of 4-bromobenzylsulfonylacetic acid (10 mmol) and 2-hydroxy-3,5-dinitrobenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 207-209°C, was obtained in 52% yield.
Example 12 (E)-2-Hydroxy-3,5-dinitrostyryl-4-chlorobenzylsufone
A solution of 4-chlorobenzylsulfonylacetic acid (10 mmol) and 2-hydroxy-3,5-dinitrobenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 204-205°C, was obtained in 51% yield.
Example 13 (E)-2-Hydroxy-3,5-dinitrostyryl-2,4-dichlorobenzyIsufone
A solution of 2,4-chlorobenzylsulfonylacetic acid (10 mmol) and 2-hydroxy-3,5-dinitrobenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 212-213°C, was obtained in 56% yield.
Example 14 (E)-2,4,6-Trimethoxystyryl-4-methoxybenzylsulfone
A solution of 4-methoxybenzylsulfonylacetic acid (10 mmol) and 2,4,6-trimethoxybenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 142-144°C, was obtained in 52% yield.
Example 15 (E)-3-Methyl-2,4-dimethoxystyryl-4-methoxybenzylsulfone
A solution of 4-methoxybenzylsulfonylacetic acid (10 mmol) and 3-methyl-2,4-dimethoxybenzaldehye (10mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 160-161 °C, was obtained in 52% yield.
Example 16 (E)-3,4,5-Trimethoxystyryl-4-methoxybenzylsulfone
A solution of 4-methoxybenzylsulfonylacetic acid (10mmol) and 3,4,5-trimethoxybenzaldehyde (10mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 138-140°C, was obtained in 54% yield.
Example 17 (E)-3,4,5-Trimethoxystyryl-2-nitro-4,5-dimethoxybenzylsulfone
A solution of 2-nitro-4,5-dimethoxybenzylsulfonylacetic acid (10mmol) and 3,4,5-trimethoxybenzaldehyde (10mmol) was subjected to the General Procedure 1, Part B. The title compound was obtained.
Example 18 (E)-2,4,6-Trimethoxystyryl-2-nitro-4,5-dimethoxybenzylsulfone
A solution of 2-nitro-4,5-dimethoxybenzylsulfonylacetic acid (10mmol) and 2,4,6-trimethoxybenzaldehyde (10mmol) was subjected to the General Procedure 1, Part B. The title compound was obtained.
Example 19 (E)-3-Methyl-2,4-dimethoxystyryl-2-nitro-4,5-dimethoxybezylsulfone
A solution of 2-nitro-4,5-dimethoxybenzylsulfonylacetic acid (10mmol) and 3-methyl-2,4-dimethoxybenzaldehyde (10mmol) was subjected to the General Procedure 1, Part B. The title compound was obtained.

Example 20 (E)-2,3,4-Trifluorostyryl-4-fluorobenzylsulfone
A solution of 4-fluorobenzylsulfonylacetic acid (10 mmol) and 2,3,4-trifluorobenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 128-129°C, was obtained in 72% yield.
Example 21 (E)-2,3,4-Trifluorostyryl-4-chlorobenzylsulfone
A solution of 4-chlorobenzylsulfonylacetic acid (10 mmol) and 2,3,4-trifluorobenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 141-142°C, was obtained in 78% yield.
Example 22 (E)-2,6-Dimethoxy-4-hydroxystyryl-4-methoxybenzylsulfone
A solution of 4-methoxybenzylsulfonylacetic acid (10 mmol) and 2,6-dimethoxy-4-hydroxybenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 134-136°C, was obtained in 58% yield.
Example 23 (E)-2,3,5,6-Tetrafluorostyryl-4-methoxybenzylsulfone
A solution of 4-methoxybenzylsulfonylacetic acid (10 mmol) and 2,3,5,6-tetrafluorobenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 154-156°C, was obtained in 56% yield.
Example 24 (E)-2,4,5-Trimethoxystyryl-4-methoxybenzylsulfone
A solution of 4-methoxybenzylsulfonylacetic acid (10 mmol) and 2,4,5-trimethoxybenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 146-148°C, was obtained in 66% yield.

Example 25 (E)-2,3,4-Trimethoxystyryl-4-methoxybenzylsulfone
A solution of 4-methoxybenzylsulfonylacetic acid (10 mmol) and 2,3,4-trimethoxybenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 154-156°C, was obtained in 52% yield.
Example 26 (E)-3-Nitro-4-hydroxy-5-methoxystyryl-4-methoxybenzylsulfone
A solution of 4-methoxybenzylsulfonylacetic acid (10 mmol) and 3-nitro-4-hydroxy-5-methoxybenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 203-205°C, was obtained in 56% yield.
Example 27 (E)-3,4-Dimethoxy-6-nitrostyryl-4-methoxybenzylsulfone
A solution of 4-methoxybenzylsulfonylacetic acid (10 mmol) and 3,4-dimethoxy-6-nitrobenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 139-141°C, was obtained in 54% yield.
Example 28 (E)-3,4-Dimethoxy-5-iodostyryl-4-methoxybenzylsulfone
A solution of 4-methoxybenzylsulfonylacetic acid (10 mmol) and 3,4-dimethoxy-5-iodobenzaldehyde -(10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 160-161°C, was obtained in 58% yield.
Example 29 (E)-2,6-Dimethoxy-4-fluorostyryl-4-methoxybenzylsulfone
A solution of 4-methoxybenzylsulfonylacetic acid (10 mmol) and 2,6-dimethoxy-4-fluorobenzaldehyde (10 mmol) was subjected to the General

Procedure 1, Part B. The title compound, melting point 146-148°C, was obtained in 55% yield.
Example 30 (E)-2-Hydroxy-4,6-dimethoxystyryI-4-methoxybenzylsulfone
A solution of 4-methoxybenzylsulfonylacetic acid (10 mmol) and 2-hydroxy-4,6-dimethoxybenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound was obtained.
Example 31 (E)-2,4,6-Trimethylstyryl-4-methoxybenzylsulfone
A solution of 4-methoxybenzylsulfonylacetic acid (10 mmol) and 2,4,6-trimethylbenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 97-99°C, was obtained in 51% yield.
Example 32 (E)-2,4,6-Trimethoxystyryl-4-chlorobenzylsulfone
A solution of 4-chlorobenzylsulfonylacetic acid (10 mmol) and 2,4,6-trimethoxybenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 181-183°C, was obtained in 54% yield.
Example 33 (E)-2,6-Dimethoxy-4-fluorostyryl-4-chlorobenzylsulfone
A solution of 4-chlorobenzylsulfonylacetic acid (10 mmol) and 2,6-dimethoxy-4-fluorobenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 119-121°C, was obtained in 55% yield.

Example 34 (E)-2-Hydroxy-4,6-dimethoxystyryl-4-chlorobenzylsulfone
A solution of 4-chlorobenzylsulfonylacetic acid (10 mmol) and 2-hydroxy-4,6-dimethoxybenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound was obtained.
Example 35 (E)-2,4,6-Trimethoxystyryl-4-bromobenzylsulfone
A solution of 4-bromobenzylsulfonylacetic acid (10 mmol) and 2,4,6-trimethoxybenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 178-181°C, was obtained in 54% yield.
Example 36 (E)-2,6-Dimethoxy-4-fluorostyryl-4-bromobenzylsulfone
A solution of 4-bromobenzylsulfonylacetic acid (10 mmol) and 2,6-dimethoxy-4-fluorobenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 116-118°C, was obtained in 58% yield.
Example 37 (E)-2,4,6-Trimethoxystyryl-2,3,4-trimethoxybenzylsulfone
A solution of 2,3,4-trimethoxybenzylsulfonylacetic acid (10 mmol) and 2,4,6-trimethoxybenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 94-96°C, was obtained in 52% yield.
Example 38 (E)-2,6-Dimethoxystyryl-2,3,4-trimethoxybenzylsulfone
A solution of 2,3,4-trimethoxybenzylsulfonylacetic acid (10 mmol) and 2,6-dimethoxybenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 110-112°C, was obtained in 54% yield.

Example 39 (E)-2,4,6-Trimethoxystyryl-,3,4,5-trimethoxybenzylsulfone
A solution of 3,4,5-trimethoxybenzylsulfonylacetic acid (10 mmol) and 2,4,6-trimethoxybenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 151-153°C, was obtained in 54% yield.
Example 40 (E)-2,6-Dimethoxystyryl-3,4,5-trimethoxybenzylsulfone
A solution of 3,4,5-trimethoxybenzylsulfonylacetic acid (10 mmol) and 2,6-dimethoxybenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 146-149°C, was obtained in 53% yield.
Example 41 (E)-4-Fluorostyryl-2,3,4-trimethoxybenzylsulfone
A solution of 2,3,4-trimethoxybenzylsulfonylacetic acid (10 mmol) and 4-fluorobenzaldehyde (10 mmol) was subjected to the General Procedure 1, Part B. The title compound, melting point 96-99°C, was obtained in 68% yield.
Example 42 (Z)-2,4,6-trifluorostyryl-4-methylbenzylsulfone
A solution of 2,4,6-trifluorophenylacetylene (0.02 mol), 4-methylbenzyl mercaptan (0.02 mol) and metallic sodium (0.02g atom) is subjected to General Procedure 2 to form (Z)-2,4,6-trifluorostyryl-4-methylbenzylsulfide. The title compound is obtained following oxidation of the sulfide, according to General Procedure 2.
Example 43 (Z)-pentafiuorostyryl-4-chlorobenzylsulfone
A solution of pentafluorophenylacetylene (0.02 mol), 4-chlorobenzyl mercaptan (0.02 mol) and metallic sodium (0.02g atom) is subjected to General

Procedure 2 to form (Z)-pentafluorostyryl-4-chlorobenzylsulfide. The title compound is obtained following oxidation of the sulfide, according to General Procedure 2.
Example 44 (Z)-pentafluorostyryl-4-methoxybenzylsulfone
A solution of pentafluorophenylacetylene (0.02 mol), 4-methoxybenzyl mercaptan (0.02 mol) and metallic sodium (0.02g atom) is subjected to General Procedure 2 to form (Z)-pentafluorostyryl-4-methoxybenzylsulfide. The title compound is obtained following oxidation of the sulfide, according to General Procedure 2.
Example 45 (Z)-pentafluorostyryl-2,3,4-trimethoxybenzylsulfone
A solution of pentafluorophenylacetylene (0.02 mol), 2,3,4-trimethoxybenzyl mercaptan (0,02 mol) and metallic sodium (0.02g atom) is subjected to General Procedure 2 to form (Z)-pentafluorostyryl-2,3,4-trimethoxybenzylsulfide. The title compound is obtained following oxidation of the sulfide, according to General Procedure 2.
Example 46 (Z)-pentafluorostyryl-3,4,5-trimethoxybenzylsulfone
A solution of pentafluorophenylacetylene (0.02 mol), 3,4,5-trimethoxybenzyl mercaptan (0.02 mol). and metallic sodium .(0.02g atom) is subjected to General Procedure 2 to form (Z)-pentafluorostyryl-3,4,5-trimethoxybenzylsulfide. The title compound is obtained following oxidation of the sulfide, according to General Procedure 2.

Example 47 (Z)-pentafluorostyryl-2,4,6-trimethoxybenzylsulfone
A solution of pentafluorophenylacetylene (0.02 mol), 2,4,6-trimethoxybenzyl mercaptan (0.02 mol) and metallic sodium (0.02g atom) is subjected to General Procedure 2 to form (Z)-pentafluorostyryl-2,4,6-trimethoxybenzylsulfide. The title compound is obtained following oxidation of the sulfide, according to General Procedure 2.
Example 48 (Z)-3-methoxy-4-acetoxystyryl-2,4,5-trimethoxybenzylsulfone
A solution of 3-methoxy-4-acetoxyphenylacetylene (0.02 mol), 2,4,5-trimethoxybenzyl mercaptan (0.02 mol) and metallic sodium (0.02g atom) is subjected to General Procedure 2 to form (Z)-3-methoxy-4-acetoxystyryl-2,4,5-trimethoxybenzylsulfide. The title compound is obtained following oxidation of the sulfide, according to General Procedure 2.
Example 49 (Z)-3,4-dihydroxystyryl-2,4,6-trimethoxybenzylsulfone
A solution of 3,4-dihydroxyphenylacetylene (0.02 mol), 2,4,6-trimethoxybenzyl mercaptan (0.02 mol) and metallic sodium (0.02g atom) is subjected to General Procedure 2 to form (Z)-3,4-dihydroxystyryl-2,4,6,-trimethoxybenzylsulfide. The title compound is obtained following oxidation of the sulfide, according to General Procedure 2.
Example 50 (Z)-2,4,6-trifluorostyryl-4-nitrobenzylsulfone
A solution of 2,4,6-trifluorophenylacetylene (0.02 mol), 4-nitrobenzyl mercaptan (0.02 mol) and metallic sodium (0.02g atom) is subjected to General Procedure 2 to form (Z)-2,4,6-trifluorostyryl-4-nitrobenzylsulfide. The title compound is obtained following oxidation of the sulfide, according to General Procedure 2.
Example 51 (Z)-2-hydroxystyryl-2,4,6-trimethoxybenzylsulfone
A solution of 2-hydroxyphenylacetylene (0.02 mol), 2,4,6-trimethoxybenzyl mercaptan (0.02 mol) and metallic sodium (0.02g atom) is subjected to General Procedure 2 to form (Z)-2-hydroxystyryl-2,4,6-trimethoxybenzylsulfide. The title compound is obtained following oxidation of the sulfide, according to General Procedure 2.
Example 52 (Z)-2-phosponatostyryl-2,3,4-trimethoxybenzylsulfone
A solution of 2-phosphonatophenylacetylene (0.02 mol), 2,3,4-trimethoxybenzyl mercaptan (0.02 mol) and metallic sodium (0.02g atom) is subjected to General Procedure 2 to form (Z)-2-phosponatostyryl-2,3,4-trimethoxybenzylsulfide. The title compound is obtained following oxidation of the sulfide, according to General Procedure 2.
Example 53 (Z)-4-phosponatostyryl-2,4,6-trimethoxybenzylsulfone
A solution of 4-phosphonatophenylacetylene (0.02 mol), 2,3,4-trimethoxybenzyl mercaptan (0.02 mol) and metallic sodium (0.02g atom) is subjected to the General Procedure to form (Z)-4-phosponatostyryi-2,4,6-trimethoxybenzylsulfide. The title compound is obtained following oxidation of the sulfide, according to the General Procedure.
Effect of (E)-Styryl Benzylsulfones on Tumor Cell Lines - Protocol 1
A. Cells.
The effect of the (E)-styryl benzylsulfones on normal fibroblasts and on tumor cells of prostate, colon, lung and breast origin was examined utilizing the

following cell lines: prostate tumor cell line DU-145; colorectal carcinoma cell line DLD-1; non-small cell lung carcinoma cell line H157; and breast tumor cell line BT-20. BT-20 is an estrogen-unresponsive cell line. NIH/3T3 and HFL are normal murine and human fibroblasts, respectively. BT-20, DLD-1 and H157 were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum supplemented with penicillin and streptomycin. DU145 was cultured in RPMI with 10% fetal bovine serum containing penicillin and streptomycin. NIH3T3 and HFL cells were grown in DMEM containing 10% calf serum supplemented with penicillin and streptomycin. All cell cultures were maintained at 37°C in a humidified atmosphere of 5% CO2.
B. Treatment with Styryl Benzylsulfones and Viability Assay
Cells were treated with test compound at 2.5 µM concentration and cell
viability was determined after 96 hours by the Trypan blue exclusion method.
Each compound tested (Exs. 1-16, 20, 21, 23-29, 31-33 and 35-40) showed
activity, inducing cell death against all tumor cell lines, in at least 5-10% of the
treated cells.
Normal cells HFL and NIH 3T3 were treated with the same compounds
under the same conditions of concentration and time. The normal cells displayed
5% growth inhibition but no appreciable cell death.
Effect of (Z)-Styryl Benzylsulfones on Tumor Cell Lines - Protocol 2
In a variation of the above assay, the effect of the (Z)-styryl benzylsulfones on normal fibroblasts and on tumor cells may be demonstrated by the assay described by Latham ef. a/., Oncogens 12:827-837 (1996). Normal diploid lung human fibroblasts (HFL-1) or tumor cells (e.g., prostate, colo-rectal, breast, glial, pancreatic ovarian or leukemic) are plated in 6-well dishes at a cell density of 1.0 x 10s cells per 35-mm2 well. The plated cells are treated 24 hours later with various concentrations of styrylbenzylsulfone dissolved in dimethyl sulfoxide (DMSO). The total number of viable cells is determined 96 hours later by

trypsinizing the wells and counting the number of viable cells, as determined by trypan blue exclusion, using a hemacytometer. Normal HFL are treated with the same compounds under the same conditions of concentration and time.
All references cited herein are incorporated by reference. The present invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof and, accordingly, reference should be made to the appended claims, rather than to the foregoing specification, as indication the scope of the invention.

WE CLAIM;
1. A substituted styryl benzylsulfone compound of the formula, having an E-
configuration or a Z-configuration:
(Formula Removed)
wherein:
(i) minimum three of R6, R7, R8, R9 and R10 are independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl, and the balance of said R6, R7, R8, R9 and R10 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano. carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; and
(ii) R1, R2, R3, R4 and R5 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl. phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy), and trifluoromethyl;
or a pharmaceutically acceptable salt thereof.
2. A compound as claimed in claim 1 wherein R1, R2, R3, R4 and R5 are halogen, same or different, and R6, R7, R8, R9 and R10 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl and C1-C6 alkoxy.
3. A compound as claimed in claim 2 wherein R8 is halogen or C1-C3 alkoxy.
4. A compound as claimed in claim 1 wherein R3 is C1-C6 alkoxy, minimum two
of R1, R2, R4 and R5 are C1-C6 alkoxy, and the remainder of R1, R2, R4 and R5 arc
hydrogen.
5. The compound as claimed in claim 1 which is (E)-2,3,4-trifluorostyryl-4-fluorobenzylsulfone.
6. The compound as claimed in claim 1 which is (E)-2,3,4-trifluorostyryl-4-chlorobenzylsulfone.

7. A compound as claimed in claim 1 wherein R6, R7, R8, R9 and R10 arc halogen, same or different, and R1, R2, R3, R4 and R5 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl and C1-C6 alkoxy.
8. A compound as claimed in claim 7 wherein R3 is halogen or C1-C3 alkoxy.
9. The compound as claimed in claim 8 which is (E)-2,3,4,5,6-pentafluorostyryl-4-fluorobenzylsulfone.

10. The compound as claimed in claim 9 which is (E)-2,3,4,5,6-pentafluorostyryl-4-chlorobenzylsulfone.
11. The compound as claimed in claim 9 which is (E)-2,3,4,5,6-pentafluorostyryl-4-bromobenzylsulfone.
12. The compound as claimed in claim 9 which is (E)-2,3,4,5,6-pentafluorostyryl-3,4-dichlorobenzylsulfone
13. The compound as claimed in claim 9 which is (E)-2,3,4,5,6-pentafluorostyryl-4-iodobenzylsulfone.
14. A compound as claimed in claim 1 wherein R3 is selected from the group consisting of halogen, nitro, cyano, C1-C6 alkyl, C1-C6 alkoxy, hydroxyl, phosphonato,
amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; and R1, R2. R4 and R5 are hydrogen; or a pharmaceutically acceptable salt thereof.
15. A compound as claimed in claim 14 wherein the compound is (E)-3,4-dimethoxy-6-nitrostyryl-4-methoxybenzylsulfone.
16. A compound as claimed in claim 14 of the formula:
(Formula Removed)
wherein:
R3 and R8 are independently selected from the group consisting of halogen, C1-C6 alkoxy, nitro, cyano, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; and
R6 and R10 are independently selected from the group consisting of C1-C6 alkoxy. hydroxyl, phosphonato, amino, sulfamyl, acetoxy and dimethylamino(C2-C6 alkoxy);
or a pharmaceutically acceptable salt thereof.
17. The compound as claimed in claim 16 wherein the compound is (E)-2-hydroxy-4,6-dimethoxystyryl-4-methoxybenzylsulfone, or a pharmaceutically acceptable salt thereof.
18. The compound as claimed in claim 16 wherein the compound is (E)-2-hydroxy-4,6-dimethoxystyryl-4-chlorobenzylsulfone, or a pharmaceutically acceptable salt thereof.
19. A compound as claimed in claim 16 wherein R6 and R10 are C1-C6 alkoxy.
20. The compound as claimed in claim 19 which is (E)-2,6-dimethoxy-4-
hydroxystyryl-4-methoxybenzylsulfone, or a pharmaceutically acceptable salt thereof.
21. A compound as claimed in claim 16, wherein R3 and R8 are independently selected from the group consisting of halogen and C1-C6 alkoxy.
22. The compound as claimed in claim 21 wherein the compound is (E)-2,6-dimethoxy-4-fluorostyryl-4-methoxybenzylsulfone.
23. The compound as claimed in claim 21 wherein the compound is (E)-2,4.6-trimethoxystyryl-4-chlorobenzylsulfone.
24. The compound as claimed in claim 21 wherein the compound is (E)-2.6-dimethoxy-4-fluorostyryl-4-chlorobenzylsulfone.
25. The compound as claimed in claim 21 wherein the compound is (E)-2,4,6-trimefhoxystyryl-4-bromobenzylsulfone.
26. The compound as claimed in claim 21 wherein the compound is (E)-2.6-dimethoxy-4-fluorostyryl-4-bromobenzylsulfone.
27. A compound as claimed in claim 21 wherein R3 and R8 are C1-C6 alkoxy. same or different.
28. The compound as claimed in claim 27 wherein the compound is (E)-2,4,6-trimethoxystyryl-4-methoxybenzylsulfone.
29. A compound as claimed in claim 1 wherein R3 is a halogen, R1, R2, R4 and R5 are hydrogen, and R6, R7, R8, R9 and R10 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy. nitro, cyano, carboxyl. hydroxyl and trifluoromethyl; or a pharmaceutically acceptable salt thereof.
30. A compound as claimed in claim 29 wherein R6, R7, R8, R9 and R10 arc
selected from the group consisting of hydrogen, halogen and C1-C6 alkoxy.
31. A compound as claimed in claim 30 wherein minimum two of R6, R7, R8- R9 and R10 are selected from C1-C6 alkoxy.
32. A compound as claimed in claim 31 wherein the C1-C6 alkoxy groups are methoxy groups.
33. A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof as claimed in any of claims 1 to 32 and a pharmaceutically acceptable carrier.
34. A compound or a pharmaceutically acceptable salt thereof as claimed in any of claims 1 to 32, for treatment of a proliferative disorder selected from the group consisting of cancer, hemangiomatosis in new born, secondary progressive multiple sclerosis, chronic progressive myelodegenerative disease, neurofibromatosis, ganglioneuromatosis, keloid formation, Pagets Disease of the bone, fibrocystic disease of the breast, Peronies and Duputren's fibrosis, restenosis and cirrhosis.

Documents:

http://ipindiaonline.gov.in/patentsearch/GrantedSearch/viewdoc.aspx?id=Mn0jiH+4Vf/DuVk8wHy9Pg==&loc=+mN2fYxnTC4l0fUd8W4CAA==

« Previous Patent

Next Patent »

Patent Number

269879

Indian Patent Application Number

1505/DELNP/2008

PG Journal Number

47/2015

Publication Date

20-Nov-2015

Grant Date

14-Nov-2015

Date of Filing

21-Feb-2008

Name of Patentee

TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

Applicant Address

BROAD STREET AND MONTGOMERY AVENUE, PHILADELPHIA, PA 19122, UNITED STATES OF AMERICA.

Inventors:

#	Inventor's Name	Inventor's Address
1	ERAGAMREDDY PREMKUMAR REDDY	547 ATTERBURY ROAD, VILLANOVA, PA 19085, UNITED STATES OF AMERICA.
2	MOOLE VENKATA RAMANA REDDY	921 ST. JOSEPH DRIVE, UPPER DARBY, PA 19082, UNITED STATES OF AMERICA.

PCT International Classification Number

A61K 31/10

PCT International Application Number

PCT/US01/12134

PCT International Filing date

2001-04-13

PCT Conventions:

#	PCT Application Number	Date of Convention	Priority Country
1	PCT/US01/12134	2001-04-13	PCT